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SUMMARY
This thesis describes investigations undertaken for a light source device embedded 
subcutaneously in the cancer treatment of photodynamic therapy. Photodynamic 
therapy involves a photosensitiser administered into tissue and using a light source to 
activate the photosensitiser leading to the destruction of tumour. An investigation into 
the current cancer treatment modality was described. The photodynamic therapy 
modality could be improved by the use of low cost LED device compared to laser 
system. The embedded LED device could be powered externally by an 
electromagnetic source.
A detailed study was performed to enable an understanding of photodynamic therapy 
process and the light-tissue interaction. A theoretical model was developed to examine 
the effect of embedding a light source and the effect of varying the photodynamic 
parameters in an effort to optimise the efficiency of photodynamic therapy.
An investigation into dielectric properties of tissues at radio and microwave 
frequencies was presented. A theoretical model was utilised to determine the 
attenuation losses in the heterogeneous tissue structures of vaiying frequencies. 
Inductive coupling and radiative coupling methods that were employed for energy 
coupling to power the LED device remotely were presented. Once the possible 
solutions were found, a complete radio frequency system and a microwave system had 
been constructed and evaluated. The evaluations carried out showed that the radio 
frequency system employing inductive coupling principle could be used to couple 
sufficient energy into tissue efficiently for the application in embedded photodynamic 
therapy.
Finally, the practical aspects of embedded photodynamic therapy were addressed. The 
findings and conclusions should be relevant to the wider biomedical cancer research 
community.
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1. Introduction
CHAPTER 1 INTRODUCTION
1.1 The Medical Needs
Current studies have shown cancer is a major cause of death in the United Kingdom 
with more than 270,000 new cases diagnosed in year 2000.m It is estimated that one 
out of three people will be diagnosed with cancer during their lifetime. Hence, there 
is a critical need in the medical field for a novel method to treat cancer effectively. 
There are more than 200 different types of cancers. The most common types of 
cancer affecting men and women in the UK are breast, lung, large bowel and prostate 
as shown in Figure 1.1.
B rta it 15%
O th«r 28%
Lung 14%
Pancreas 3%
Oesophagus 3%
Head and neck 3%
Non-Hodgkin's lymphoma 3%
Stomach 4%
Bladder 4% Prostate
ALL MALIGNANT NEOPLASMS" -
NOTE percentage* may 
not add due to  rounding
Large bowel 13%
10%
2 7 0 .4 2 5
Figure 1.1: Ten most common cancers diagnosed in the UK. [1]
Cancer is an uncontrolled growth of cells that destroy normal tissues. The cancer 
cells are tumours which destroy the part of the body in which they are formed and 
then spread to other parts where they start a new growth and cause more cell 
destruction. The abnormal cells keep reproducing and do not mature into normal 
cells. With each doubling of cells, the cells become more primitive and reproduce 
more rapidly. The genetic information in the cancer cells are damaged or lost. It is 
this ability to spread fast that makes a cancer highly dangerous which has to be 
treated immediately.
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1.1.1 Limitation in Current Treatment
The current cancer treatments are surgery, radiotherapy, chemotherapy, 
immunotherapy, gene therapy and stem cell transplant Immunotherapy is the 
treatment with substances to boost the immune system of the body to fight against 
cancer cells. The gene therapy and stem cell transplant treatments are still in the early 
development stage of treating cancer safely but hold the solution to cure all types of 
cancer.
Surgery is one of the main methods of cancer treatment. It is mostly used to remove 
the tumour in only one particular part of the body and not suitable for patients whose 
cancer has spread to another part of the body. However, every surgery performed 
always carries some risks due to the trauma involved. There is always the danger that 
malignant tumours have already spread before surgery. There are some common 
problems associated with surgery. These are
• Pain.
• Local infection.
• Blood clots.
• Scarring.
• Fluid collection around the wound.
Traditional cancer therapies such as chemotherapy and radiotherapy have major 
drawbacks and work in the same way as carpet bombing. These methods destroy not 
only the cancer cells but also other healthy cells in the body. These therapies result in 
the loss of normal cell function because of having non-selectivity in targeting cancer 
cells. The radiotherapy and chemotherapy can be used to
• To shrink a cancer before surgery.
• To reduce the risk of a cancer coming back after surgery.
• To cure a cancer completely.
• To control symptoms and provide quality of life when a cancer is too 
advanced to cure.
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Radiotherapy is the treatment using high energy rays to kill cancer cells. The high 
energy rays are directed at the localised part of the body being treated. To protect 
normal cells, doctors carefully limit the doses of radiation and spread the treatment 
out over time. They also shield as much normal tissue as possible while they aim the 
radiation at the site of the cancer. The most common side effects of radiotherapy are
• Tiredness.
• Anaemia.
• Skin problems.
• Damage to normal tissues.
• Hair loss in the treatment area.
• Infertility.
Chemotherapy is treatment with anti-cancer drugs to destroy cancer cells. Drugs can 
be injected intravenously or taken orally. It is a systematic method that can be used 
to treat cancer anywhere in the body because it circulates throughout the body in the 
bloodstream. Anti-cancer drugs destroy cancer cells by stopping them from growing 
or multiplying. The most common side effects of chemotherapy are
• Fatigue
• Damage to body organs
• Lowered resistance to infection
• Reduction in memory and concentration abilities
• Increased risk of getting another type of cancer
• Infertility
All of the cancer treatments mentioned above do not effectively target and kill cancer 
cells and have lots of long term side effects. With these complications and health 
problems assiociated with conventional cancer treatments, there is a serious need for 
a better treatment protocol to treat cancer effectively with fewer side effects. Another 
alternative method of treating cancer is the photodynamic therapy (PDT).
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Recently photodynamic therapy has been utilised as the new cancer treatment for a 
range of cancers. The concept of photodynamic therapy is the combination of two 
agents, a photosensitising drug and light. This requires a systemic application of a 
drug containing a photosensitiser. The drug preferentially attaches itself to a diseased 
cell and remains at that location for a defined time. Illumination of the 
photosensitiser using a specific light wavelength leads to a selective tumour damage 
or destruction as shown in Figure 1.2. In the past, photodynamic therapy is being 
offered when all other cancer treatments have failed. Now, it is the preferred 
treatment for certain types of cancer due to its tumour selectivity and low side effects 
combined with high success rate. Figure 1.3 shows a patient undergoing PDT with 
red laser irradiated on the skin and Figure 1.4 shows the patient successful treatment 
results.
P a t ien t  \ \ i t h  
t u m o u r
P h o to s e n s i t i s e r
a p p l i c a t i o n
P h o t o s e n s i t i s e r
r e d i s t r i b u t io n
L ig h t
i r r a d i a t io n
T u m o u r
d e s t r u c t io n
Figure 1.2: Treatment of cancer with photodynamic therapy.1331
Figure 1.3: A patient undergoing photodynamic therapy treatment.1331
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Figure 1.4: Images of a patient before and after PDT treatment results.l3?l
Photodynamic therapy is a technique which holds great promise; however its usage is 
limited by a number of factors:
I. Following an application of a photosensitiser, the tumour is illuminated by a 
laser. This illumination is invariably direct line of sight, thereby limiting the 
treatment to only surface or superficial tumours.
13. Since the laser systems utilised in the PDT are large and expensive, the 
treatment modality is relatively resource intensive. This includes the need for 
dedicated treatment rooms reflecting significant capital investment
III. In order to achieve maximum therapeutic benefit, significant drug dosages are 
utilised. Drugs are applied some time before exposure by laser to allow tumour 
uptake. The patient is then treated in a relatively short time minimising 
occupation of the treatment room. A major disadvantage of photodynamic 
therapy is that the patient develops prolonged photosensitivity to visible light 
for several weeks following the treatment.
5
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1.1.2 Improvement to Current Treatment
Lasers are currently the most widely used light sources in cutaneous application to 
treat aged, damaged and cancer cells. In photodynamic therapy, high power laser are 
used to stimulate photochemical reactions between photosensitiser and oxygen. The 
laser’s monochromatic light permits precise photosensitiser activation at the 
wavelength of one of its absorption peaks.
Despite these advances, laser systems are still large, expensive, and complicated to 
operate. Broadband non coherent light sources are typically smaller, safer to use, and 
less expensive to operate than laser. The development of a non coherent light source 
that is inexpensive could make PDT recognised as a first choice for cancer treatment. 
A light emitting diode (LED) device provides the alternative low cost solution for the 
expensive laser. LED arrays are much smaller and produce low irradiances and can 
be used to illuminate large tumour area.
The objective of this research is therefore to develop a new method to couple energy 
to a subcutaneous device that emits the required optical parameters for photodynamic 
therapy. The proposed device will be embedded into the skin and remotely powered 
by radio frequency (RF) coupling. The illumination from the subcutaneous LED will 
activate the photosensitiser for photodynamic therapy leading to consequent 
destruction of the cancer cells.
This research has two main objectives
I. To develop a computer model that simulates the light distribution of photon 
energy absorption in tissue and to investigate the photodynamic 
mechanism.
II. To investigate the RF-tissue interaction and to develop a method to couple 
energy required into tissue efficiently in order to power the LED device.
6
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1.2 PDT Light Device
Although lasers remain good light sources for PDT of localised disease such as 
superficial basal cell carcinoma cancer, lasers cannot penetrate deeply into the body 
without causing much surface heating. Laser systems are expensive and complex to 
use and require a dedicated treatment room. This creates a demand for an efficient 
and low cost light source for PDT use. In order to meet the demand of medical needs 
and to improve the PDT treatment, a RF-LED based light device has been proposed.
The ideal RF-LED based light device requirements:
• Small in size, lightweight and implantable.
• Have a LED wavelength matched to the photosensitiser.
• Powered by RF energy coupling from an external source.
• Encapsulated in a biocompatible material.
The PDT light device consists of two main parts
• Light source.
• Power source.
1.2.1 Light source - LED
The benefit of using an implantable LED is that the light source is positioned closely 
to the tumour thus allowing deep treatment depth whereas laser can only penetrate 
superficially with most photons being absorbed into the skin before reaching the 
tumour. The layer of the skin will be intact without the undesirable heating and 
pigmentation frequently caused by laser. The efficacy of the PDT treatment will 
increase with only the tumour area being illuminated by LED and leaving the normal 
tissue unharmed. For this reason, it is reasonable to propose that the use of a low 
power LED positioned subcutaneously may be significantly more efficient than a 
higher power external laser that is directed at the surface of the skin. The LED device 
is much cheaper to manufacture and do not require complex circuitry compared to a 
laser system.
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1.2.2 Power Source - RF Coupling
The LED light source will be powered by an external source through radio frequency 
coupling, this means that the embedded device does not requires a battery. It is 
proposed that by using radio frequency, energy can be transferred through multiple 
layers of tissue without much loss and heating. The benefit of using RF coupling is 
that the LED can be left in the patient’s body indefinitely or until the tumour has 
been destroyed. The total fluence of light can be controlled and pulsed depending on 
the patient’s need. Patients will have a better treatment modality compared to 
conventional laser treatment. They are not required to be confined to the treatment 
room and are able to lead a normal lifestyle. The embedded LED powered and 
controlled externally by using pulsed or continuous PDT effect. The photosensitiser 
dosage could be reduced and controlled over a longer duration of photodynamic
therapy for increased treatment efficiency. This could benefit the patient by lowering
the patient’s skin photosensitivity.
The possible benefits of PDT light device:
• Light source can be positioned in the region of interest.
• Controlled dose of photosensitiser.
• Controlled dose of light.
• Higher photodynamic selectivity and damage.
• Enhanced treatment efficacy.
• Improved patient treatment regime.
• Lower cost of treatment.
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1.3 Photodynamic Therapy
The medical definition of photodynamic therapy is the treatment of diseased cells by 
the use of visible or infrared light together with an administered photosensitiser and 
in the presence of oxygen. Light is absorbed by the photosensitiser, which in turn 
releases singlet oxygen. The reactive singlet oxygen then causes damage or 
destruction of the tumour tissue.
1.3.1 Historic Review
In 1903, Von Tappeiner had published experiments on photodynamic therapy in 
which tumours had been treated with Eosin, a photosensitiser dye, and exposed to 
visible light.121 Von Tappeiner showed that PDT was effective for treating skin 
cancer. Ten years later, Meyer-Betz was the first to demonstrate long-term cutaneous 
photosensitivity after injecting himself with Hematoporphyrin.[3] Photodynamic 
therapy was shown to be a promising new modality in the treatment of cancer since 
the early 1960s. Lipson et al. created a photosensitiser drug called Hematoporphyrin 
Derivative (HPD) that could be localised with some degree of selectivity in tumour 
tissue.141 Lipson et al. were also the first to use xenon arc lamp to activate HPD in a 
patient with recurrent breast cancer.151 HPD was investigated as a diagnostic agent for 
cancer in which PDT remained an important application during the 1970s. Diamond 
et al. showed that by changing the irradiation conditions, the photodynamic effect 
could be achieved and the tumour could be photodegraded.[31 Diamond et al. also 
introduced the term photodynamic therapy. In 1974, Dougherty et al. showed that 
PDT was possible using HPD and light in the treatment of malignant tumours with 
complete effectiveness in animals and in patients.16,71 Extensive fundamental and 
clinical research using porfimer sodium as a photosensitiser was carried out for a 
variety of malignant cancers.
There has been much development in recent years for new photosensitisers that 
achieve high selectivity in targeting the cancer tissues, thus increasing the efficiency 
of the treatment. Porfimer sodium under the trade name Photoffin® was the first 
photosensitiser approved by the United States Food and Drug Administration (FDA)
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in 1995 and it is now licensed for use in the treatment of esophageal, lung, gastric, 
cervical, and bladder cancers.|X| At the same time, there has been increasing research 
in the development of second generation photosensitisers which are more efficient 
and more tumours specific.
1.3.2 Treatment Modality
The cytotoxic tumour action of PDT is a two-phase process as shown in Figure 1.5. 
The first phase is the intravenous injection of the photosensitiser. For systemic 
photosensitiser, the total patient drug dose is usually based on body weight ( 2mgkg 1 
for Photofrin®). After the administration of photosensitiser, the patient’s skin and 
eyes will be very sensitive to sunlight and bright light for at least thirty days and may 
remain photosensitive for up to ninety days. Before the light exposure, a delay is 
necessary to allow photosensitiser distribution and partitioning between target cells 
and normal cells. Photosensitiser clearance ffom tissues occurs over 40-50 hours, but 
the tumours retain photosensitiser at a higher concentration for a longer period.181
Application Accumulation Therapy
Photosensitiser
Figure 1.5: Two-phase process of PDT treatment.[91
The illumination with laser light at 40-50 hours after injection represents the second 
phase of therapy. A second light application may be given 96-120 hours after 
injection to ensure all photosensitiser are used completely. The doctor will direct the 
laser light to its target through a fibre optic endoscope. The fibre optics specially 
designed to emit laser light are thin, flexible, transparent strands. Treatment times 
vary substantially and the time is related to the absorption of light by the 
photosensitiser and the efficiency of light energy transfer to oxygen. A burning
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sensation during the irradiation also occurs and can be controlled by local 
anaesthetics when necessary.[9J The tumour cells death occurs through cellular 
damage and necrosis during the treatment Post treatment pain is usually milder and 
responsive to oral analgesics.
After the treatment, the patients are advised to avoid direct exposure to sunlight and 
bright light. However they do not have to limit themselves to dark rooms. It is 
helpful to get some low power indoor light, because the low levels of light will help 
break down the drug in the body and reduce photosensitivity in the patients. The 
complete healing of treated area generally occurs within 4 to 8 weeks after treatment. 
For tumours to be completely destroyed, PDT has been repeated up to two or three 
times at intervals of 3 weeks to 3 months.110,11]
There are two common side effects associated with PDT treatment.[8]. First, local 
swelling and inflammation occurring in and around the treated area may cause 
physical discomfort including pain in the chest, back, or abdomen and breathing 
difficulties. The second short term side effect is photosensitivity due to the continued 
presence of the drug in the skin.
1.3.3 Mechanism of Action
The PDT is a photochemical interaction that is dependent on three most important 
elements -  oxygen, photosensitiser and light source. Photosensitiser has the ability to 
preferentially accumulate in cancer tissue and much less in normal tissue. Each 
element is harmless by itself but when the photosensitiser is activated by specific 
wavelength of light and reacts with oxygen, the end result is singlet oxygen. This 
singlet oxygen is highly cytotoxic with a short lifetime that can cause damage to the 
micro vasculatures of tumour.[9] The selectivity of PDT is enhanced by the increased 
uptake of the photosensitiser by diseased tissue and the confinement of the 
photosensitiser activation by restricting irradiation to only tumour area.
During PDT, the photosensitiser in the tissue is first excited by light from the ground 
state to a short lived, higher-energy singlet state followed by a transition to the
11
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reactive triplet state as shown in Figure 1.6.[121 The long lifetime of triplet state 
enables the photosensitiser to react with surrounding molecules to form either singlet 
oxygen or radical ions. The reactive triplet state can react in two ways as defined by 
Type I mechanism and Type II mechanism shown in Figure 1.7.[13’141
The Type I mechanism involves electron transfers between the triplet state sensitiser 
and cellular substrate to form free radical ions. These free radicals are highly 
unstable and will react with molecular oxygen to produce reactive oxygen species. 
The reactive oxygen species produce oxidative damages that are expressed as 
biological lesions.
The Type II mechanism requires energy transfer between the triple state sensitiser 
and ground state oxygen to generate singlet oxygen molecules. These singlet oxygen 
molecules are extremely reactive and will interact with the surrounding cells to 
induce oxidative damages and cell necrosis. The Type II process predominates in 
PDT and generates the cytotoxic effect of PDT.[ 15,161 Under low oxygen 
concentration conditions, Type I mechanism becomes more dominant than Type II 
process.1121 Tissue oxygen concentration compared with photosensitiser 
concentration can be a limiting factor for PDT in some conditions.1171
Singlet
state
Photochemical reaction
• Type I
• Type II
60 60
Ground state
Figure 1.6: Photosensitiser activation by light
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Light
Sensitiser ------- ► Sensitiser *
1 Sensitiser * ....... ► 3Sensitiser*
Tvne I Mechanism
3Sensitiser * + 3Sensitiser * ------- ► Sensitiser + Sensitiser
3Sensitiser * + Substrate ------- ► Substrate + Sensitiser
Sensitiser "*+ 0 2(3Xg-) ------- ► Sensitiser+ O2
Substrate "*+ C>2(3Zg-) ------- ► Oxidative damage
Substrate + O2 “* ------- ► Oxidative damage
Tvne II Mechanism
3Sensitiser * + C>2(3Zg-) -------► Sensitiser+ 0 2(1Ag)
02(!Ag) + Substrate -------► Oxidative damage
* is the excited state, •  is the radical state
Figure 1.7: PDT mechanism of action (Type I and Type II).
1.3.4 Light Sources
Although LED arrays are currently the most widely used PDT light sources, their 
usage in PDT differs fundamentally from that in other cutaneous laser applications. 
In PDT, lasers are used for photochemical reactions between photosensitiser and 
oxygen, while the clinical effects of laser are the result of photothermal interactions 
between the photons and chromophores present in the skin. For the photothermal 
interactions, the principle of selective photothermolysis applies which is dependent 
on laser wavelength and pulse duration.[18] For PDT, photosensitiser dose and total 
light fluence are the important variables determining the treatment efficacy. 
However, lasers are absolutely required for selective photothermolysis, whereas PDT 
can be carried out with laser and also with non-coherent broadband light sources.
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Lasers have become the standard source for PDT application because they can be 
efficiently coupled to flexible fibre optics to allow access to internal tissues and their 
monochromatic property allows precise and efficient photosensitiser activation at its 
absorption peak. Another relative advantageous of laser is their ability to deliver high 
irradiances at specific wavelength, thereby minimising overall treatment times. 
However, this is not necessary in PDT because low fluence rate can cause more 
damage than high fluence rate for the same total fluence.1191 At high fluence rate, the 
amount of damage may reach a threshold and fractionation of the light delivery 
appears to increase the amount of damage produced by a given fluence.[20] This is 
because for a higher fluence rate, the tissue oxygen concentration is rapidly depleted 
without recovery, thereby quenching the reaction.f211 Fractionation of light with short 
pulse duration was shown to be more effective for PDT than continuous wave 
light.1221 This is due to short period of oxygen recovery during the dark interval 
resulting in more singlet oxygen production. Sterenborg and Van Gemert suggested 
that at irradiances several-times higher than the photosensitiser saturation level, PDT 
effects depend only on the actual photosensitiser tissue concentration and not on the 
local irradiance.[231
The broadband non-coherent light sources are typically smaller, easier to use and less 
expensive to acquire than laser system. These include xenon arc lamps, flash lamps 
and fluorescent tubes. The advantageous of these sources are the capability for 
irradiating a large treatment area and photosensitiser activation at multiple 
wavelengths for drugs that exhibit several absorption peaks. Light exposure can 
sometimes generate active photoproducts with absorption peaks that are different 
from the parent photosensitiser. Some of these photoproducts can be triggered to 
enhance the overall PDT effect.1231
The development of alternative non-coherent light sources that are inexpensive and 
light weight will undoubtedly make PDT more practical for routine daily use. 
Current high intensity LED arrays system available are portable, produce high 
irradiance (>10Wcm"2) within a narrow band (±10nm) and represent a technology 
that is much less expensive than laser system.
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For most photosensitisers that have multiple absorption peaks, the effective treatment 
depth of PDT is determined by the tissue penetration of the activating wavelength of 
light used. To achieve deep photodynamic effect, photosensitisers with high 
absorption at longer wavelengths are desirable when treating tumours. Above 750nm 
wavelength, PDT efficiency is limited because the photon energy may be insufficient 
to drive photochemical reactions.1241 In contrast, shorter wavelengths are preferable 
for superficial photodynamic effect or when deep photodynamic effects are not 
needed.
1.3.5 Photosensitisers
Photosensitisers are compounds that are capable of absorbing light of specific 
wavelength and transforming it into functional energy for the production of reactive 
agents. Most photosensitisers are administered systemically and some are applied 
topically in the treatment of skin cancer. There are hundreds of natural and synthetic 
dyes that can function as photosensitisers for PDT, ranging from plant abstracts to 
complex synthetic macrocycles. The important attribute of any photosensitiser is the 
ability to selectively accumulate in cancer cells and generate enough cytotoxic agents 
to cause destruction of cells.
There are a number of photosensitiser agents available today for PDT with the most 
commonly used being the porfimer sodium and protoporphyrin. These 
photosensitisers are the first generation photosensitisers approved by the regulatory 
authorities and are marketed with the name Photofin® (Axcan Pharma Inc.) and 
Levulan® (Dusa Pharmaceuticals Inc.) respectively.
Photoffin® or porfimer sodium (Figure 1.8) has been accepted in the clinic in 
several countries for the treatment of early and late stage lung cancer, superficial and 
advanced oesophageal cancer, bladder cancer, superficial and early-stage gastric 
cancers, early stage cervical cancer and cervical dysplasia.1141 In addition, porfimer 
sodium is being investigated in clinical trials with promising results for conditions 
such as cancers of the head and neck, brain, intestine, lung, breast and skin.
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With the success of porfimer sodium to treat oesophagus and lung cancer, the first 
generation photosensitiser still has a few disadvantages. Although porfimer sodium 
has a range of absorption wavelength (400-650nm), the 630nm wavelength is used 
clinically for tumour treatment because of its deeper tissue penetration, but the 
absorption band at this wavelength is the weakest, therefore the depth of effect is 
limited to 0.5 cm.[9] The other disadvantage is that porfimer sodium is retained by the 
cutaneous tissue and induces skin photosensitivity that lasts for 4 to 6 weeks.[25] 
Photosensitivity appears to be dose dependent according to preliminary clinical 
studies.126,271 Hence, patients are required to avoid sunlight and bright artificial light 
for the duration of photosensitivity. These problems of prolonged photosensitivity, 
limited light penetration into tissue and the 48 hours delay required between drug 
infusion and light treatment associated with the photosensitiser have been addressed 
partly by the development of second generation photosensitisers.
\H
NH HN
CH3CHOH or CH2CH 
(Photofiin®)
Figure 1.8: Schematic structure for Photofiin®. [l41
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Levulan® or 5-aminolevulinic acid (Figure 1.9) is a naturally occurring molecule 
present in the human cells, and to date it has received approval only for a non- 
malignant disorder, actinic keratosis. The ALA is not a photosensitiser by itself, but 
the ALA is converted to protoporphyrin IX, a photosensitiser with photodynamic 
activity. The administration of ALA is by a topical route and can be activated by 
many light sources. The optimal wavelength for the in vivo photodynamic activation 
of protoporphyrin IX has been shown instances with hamsters to be 635 nm.[28] It is 
used mainly for cutaneous lesions such as basal-cell carcinoma due to its limited 
penetration depth.[ 101
The ALA has been actively used in dermatology and currently exhibits the best 
topical efficacy of any PDT drugs. Its smaller molecular size renders it more 
permeable across the skin than porphyrins. The concentrations of ALA used in 
topical applications are 5% to 20%. Also, localised photosensitivity occurs after 
treatment and the patients must avoid sunlight to treatment sites. While the absence 
of systemic photosensitivity is a definite advantage in topical application, cutaneous 
ALA penetration can be highly variable from one patient to another.[29J
NH2CH2COCH2CH2CO2H 
(5-Aminolevulinic Acid) HN
protoporphyrin IX
Figure 1.9: Schematic structure and conversion of ALA to protoporhyrin IX [I4]
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Although the first generation photosensitisers are widely used for PDT treatment, 
there are a few disadvantages associated with them. The first of the disadvantages is 
that the photosensitisers are not selective enough and remains in normal tissue for 
several weeks thus causing prolonged photosensitivity. Secondly, the absorptions of 
light at 630nm of the photosensitisers are the weakest. Hence, the low energy 
absorptions require higher photosensitiser doses and higher light doses if adequate 
level of excited photosensitiser is to be generated.
The development of second generation photosensitisers should have reduced the 
photosensitivity duration, longer activation wavelengths and therefore increased 
depth of penetration, higher damage by singlet oxygen, and better tumour selectivity. 
The photosensitiser groups that have been most actively investigated are Temoporfin, 
Texaphyrins, Tin-Etiopurpurins, and Phthalocyanines. These second generation 
photosensitisers have absorption bands between 640nm and 750 nm, being 
administered systemically and induced cutaneous photosensitivity for 5 to 10 days 
only.
Temoporfin or metatetraphyroxphenylchlorin (m-THPC) under the tradename 
Foscan® (Biolitec Pharma Ltd.) is a very potent photosensitiser in current 
development. This photosensitiser is one of the most cytotoxic of all the second- 
generation photosensitiser with a quantum yield of singlet oxygen of about 0.87 and 
with a residual photosensitivity up to two weeks.191 It has been used for curative, 
palliative or adjuvant treatments of head and neck cancers.130,311 It requires very low 
drug doses (0.15mgkg_1) as well as very low light dose (20 Jem'2) making it 100 
times more reactive than Photofrin®, which requires high drug dose (2-5 mgkg'1) 
and high light dose (100-200 Jem'2).1141 In 2001, Foscan® has been approved in the 
Europe Union, as a local therapy for the palliative treatment of patients with 
advanced head and neck cancer who have failed prior therapies and are unsuitable for 
radiotherapy, surgery or chemotherapy. Foscan® is also on clinical trials for late 
stages oesophageal cancer and dysplasia in Barrett’s oesophagus. In addition, topical 
formulations of temoporfin are being developed to compete with ALA against skin 
cancers and other dermatological conditions.1141
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The successes of Photofrin® and other second-generation photosensitiser have 
created a huge growth in treatment of cancer with PDT. Another photosensitiser drug 
currently under investigation is Hypericin. Hypericin is well documented as having 
photodynamic activity as it causes photo poisoning in animals that consume large 
quantities of plants containing this compound, often leading to skin irritation, fever 
and even death.1321 Hypericin which absorbs light at 590nm, is currently on phase I 
clinical trial studies for the treatment of psoriasis, warts and skin cancer.
At present, the pharmaceutical industry is investigating new types of chromophore 
that can produce a photodynamic effect upon illumination and therefore will have the 
possibility in the future of treating many types of cancer with greater efficacy.
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CHAPTER 2 LIGHT-TISSUE INTERACTIONS
2.1 Light Transport in Tissue
As the application of lasers and LEDs in medical field becomes increasingly 
important, an understanding of light interaction with the biological tissue is essential. 
The interaction of light and tissue depends on the characteristics of the light source 
and the target tissue. The distribution of photons in the tissue is basis for 
photochemical therapy or photothermal therapy. Three interactions take place when 
the light enters upon biological tissue, it can be subject to reflection, scattering, and 
absorption through the material. Tissue is a scattering and absorbing medium which 
has a higher refractive index than air. A portion of light will undergo reflection at the 
surface of the skin while the remainder will interact in some way with the tissue. The 
light penetrates the tissue and goes through multiple scattering and absorption events. 
Scattering events occur when there is a change in the propagation distribution of 
incident light. Absorption events occur when the photon transfers its energy to an 
atom or a molecule known as a chromophore. Chromophores are substrates in the 
tissue that absorb the light and exhibit multiple bands of absorption at specific 
wavelengths.
2.1.1 Light Scattering
As light strikes the skin surface, about 5% of light reflected from skin is scattered 
light because of the sudden change in refractive index between air and stratum 
comeum.t34] When the remaining 95% of the light propagates into the tissue, it 
encounters multiple scattering and absorption events. The path of direction of light 
propagation changes because of the complex geometry of bio molecules and the 
inhomogeneous distribution of tissues in human body.1351 A small momentum is 
imparted by scattering and the photon continues along its way in different direction 
until it has been absorbed or back-scattered out of the tissue. In a highly scattering 
tissue, a large proportion of the photons are back-scattered out of the tissue, which 
depends on the wavelength. The size of the molecules or particles in the tissue
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relative to the wavelength of incident light determines the spatial distribution and 
intensity of the scattered light
For particles which are much smaller than the wavelength of light, Rayleigh 
scattering theory applies where scattering dominates at longer wavelength.t36] The 
scattering is weak, nearly isotropic and varies inversely with the fourth power of the 
wavelength
Mie scattering theory applies when the particle size is comparable to or larger than 
the incident wavelength.[37] The scattered particle is rather wavelength independent 
and is highly forward directed. Mie scattering tends to dominate over Rayleigh 
scattering in the band of wavelengths commonly used in the laser therapy. At longer 
wavelength, Rayleigh scattering becomes more dominant as the wavelength is 
increasingly larger than the particles size.
The distribution of scattering events is determined by an isotropic component and the 
phase function. The variation from isotropic scattering is given by the anisotropy 
factor.
2.1.1.1 Phase Function
In order to determine the angular distribution of scattered light, the phase function of 
scattering is used. The direction in which a photon will scatter in each event depends 
on an angle obtained from a phase function. The phase function represents the 
product of the tissue’s albedo and the probability density function that a photon 
moving from one direction will be scattered into the different direction. The albedo is 
defined as the ratio of scattering coefficient to the total attenuation coefficients. It is 
assumed that the scattering depends only on the angle between unit vector directions 
s and s’. The scattering probability phase function p(s,s’) can be written as
pis, S') = p{9) (Eq. 2.1)
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If the scattering is isotropic, then the phase function becomes a constant.
(Eq. 2.2)
The majority of the scattering occurring in tissue is in the forward direction as light 
scattering in tissue is not isotropic. The Henyey-Greenstein phase function is used to 
represent forward scattering in tissues because it provides a reasonable 
approximation of scattering in the visible wavelengths.139,40,411
The Henyey-Greenstein phase function is defined by [391
In a highly scattering medium, a substantial amount of light is back-scattered out to 
the tissue surface. The back-scattered light could either leave the tissue and be 
transmitted into the air or totally internally reflected. The refractive index of the 
medium determines the critical angle. The back-scattered light that exceeds the 
critical angle will undergo total internal reflection.
The critical angle is given b y [40]
The type of tissue, wavelength and temperature changes affect the angle of incidence 
at the surface of tissue. It has been discovered that as much as 75% of incident beam 
may be reflected out of the tissue due to back-scattering.f34,421
(l + g2-2 g co s# )^
(Eq. 2.3)
6C = sin-1 i (Eq. 2.4)
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2.1.1.2 Anisotropy Factor
The anisotropy factor is used to determine the diffusion pattern of the light as it 
penetrates the skin. This parameter represents the mean cosine of the scattering 
angle.
The anisotropy factor, g, is defined b y [40]
where 6 is the scattering angle
p(ju) is the probability density function
The quantity of ‘g ’ characterise the angular distribution of beam scattering.
when g = -l light is entirely backscatter 
g =  0 light is isotropic scatter 
g = +1 light is purely forward scatter
Isotropic Scattering
+i
(Eq. 2.5)
-l
When g = 0 p{0) = constant
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Slightly Forward Scattering
When g = 1/6 p{6) -  constant [1 + 3g cos 0]
P(0)
Forward Scattering
When g = 0.78 p(0) =  v
(l + g 2-2 g co s0 )^
P(0)
Van Gemert et al had derived a simple formula that is used to calculate ‘g’ value for 
highly scattering non-vascular layers of the skin.[38]
g » (Ax0.29x10_3)+0.62 (Eq. 2.6)
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2.1.2 Light Absorption
Another process of laser tissue interaction that occurs in the tissue is the photon 
absorption. Light energy is absorbed when the incident light excites a molecular 
resonance. Once it is absorbed, the photon energy is transferred to the chromophore 
and the photon ceases to exist. The chromophore becomes excited and may trigger 
photochemical, photothermal or photomechanical reaction. The probability that the 
reaction will occur depends on the total light dose and the light intensity.
The absorption spectrum of the major skin chromophores dictates most of the laser 
tissue interactions in the medical field. Human skin has distinctive cell structures that 
have different absorption spectra. The skin is a highly water based structure which 
comprises of 60% to 70% water and 30% to 40% organic molecules.1431 This 
heterogeneity allows the selectivity of target choromophores for selective 
photothermolysis or selective photochemical to work. The primary target 
chromosphores for the skin in the visible wavelengths range are the melanin and the 
haemoglobin. Figure 2.1 shows a three dimensional view of the human skin and its 
three main layers: the epidermis, the dermis and the hypodermis.
Figure 2.1: Three dimensional view of the human skin.11041
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2.1.2.1 Tissue Chromophores
Water exhibits strong absorption for far-ultraviolet region of wavelength below 
200nm and in the far-infrared region of wavelength above 1200nm as shown in 
Figure 2.2. The advantageous of this spectra is that light energy only penetrates about 
30pm into the surface of the skin if a 10.6pm wavelength CO2 laser is used and is 
therefore excellent for skin resurfacing.1441 At 1200nm and above wavelengths, the 
optical properties of tissue are assumed to be similar to the optical properties of 
water.
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Figure 2.2: Absorption spectrum of water from 200nm to 200pm wavelengths 158 591
Absorption by melanin dominates the epidermal optical properties for wavelength of 
250nm to 1200nm (see Figure 2.3). At a far-ultraviolet region, melanin absorption is 
greater due to its role as a skin protector against ultraviolet sunlight damage from 
sunlight.1451 Melanin absorption is also dependent on the type of skin. For fairer skin, 
the transmission of light increases steadily from about 50% at 400nm to 90% at 
1200nm while dark skin transmit light less 20% throughout the visible spectrum and 
rises to 90% at 1200nm.[461
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In contrast, the blood absorption is dominated by absorption of oxygenated 
haemoglobin and absorption of deoxygenated state haemoglobin (see Figure 2.4). 
Oxyhaemoglobin exhibits strong absorption at 420nm and 577nm while haemoglobin 
has an absorption peak at 560nm.[47l  Despite the high absorption of oxyhaemoglobin 
in the 420nm, limited penetration and high absorption of melanin make this region 
not suitable for use. The 577nm was selected for targeting superficial microvessels 
by selective photothermolysis because it is strongly absorbed by the blood.[48] 
Another wavelength chosen for selectively targeting large blood vessels is the 585nm 
because the depth of penetration is higher than the 577nm.[49] Beyond 600nm, 
absorptions by oxyhaemoglobin and haemoglobin are negligible.
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Figure 2.3: Absorption spectrum of melanin in the human skin t6^ 61’62!
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2.1.2.2 Absorption and Scattering Coefficient
A metric is defined for each of the scattering and absorption events namely 
absorption and scattering coefficient respectively. These coefficients represent the 
optical properties for various types of tissue.
The absorption coefficient, jua, is defined as the average number of absorptions per 
unit path length of photon travelled in the tissue. Similarly, the scattering coefficient 
/^is defined as the average number of scatterings per unit path length of photon 
travelled in the tissue
In the presence of both absorption and scattering, the total attenuation coefficient ju, 
is defined by
fJ, = K + M  (Eq. 2.7)
The mean free path between absorption events is equal to 1/n a . Similarly, the mean 
free path between scattering events is equal tol///s .
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2.1.3 Light Distribution Models
The photon incident on the tissue experiences multiple scattering and absorbing 
events. In order to describe these light distribution events in the tissue, numerical 
models are used to provide solutions to the laser-tissue interaction. The numerical 
models can be divided into two types, deterministic and probabilistic. Deterministic 
solutions are based on a theoretical model. The most widely used theoretical models 
are the Lambert-Beer’s Law, Radiative Transport Theory and Diffusion 
Approximation Theory. Probabilistic solutions involve generation of random 
numbers in order to simulate some random process found in the original problem. 
The method of using probabilistic solution to simulate the light distribution is called 
the Monte Carlo method.
2.1.3.1 Lambert-Beer’s Law
If absorption dominates scattering (//a » / / , ) ,  the light exhibit exponential 
attenuation when it is passed through the tissue with increasing depth. ^
This distinctive decay in intensity is called Lambert-Beer’s law which states that the 
intensity at depth z is given b y [34]
/ ( z )  =  I 0 exp [ - ( / / .  + / / > ]  (Eq. 2.8)
where 70 is the intensity of the incident light at z = 0.
The above equation is valid for modelling 1-D geometries. In 2-D modelling, the 
spatial profile of the laser beam needs to be included. A Gaussian distribution profile 
is considered with e'2 radius of w which the intensity at a point (z,r) is given b y [341
-2 r 2
I ( z , r )  = /„exp[— -— (^ ,,+ ^ J z ]  (Eq. 2.9)
w
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The probability of the photon being either absorbed or scattered at a particular point 
can be calculated using the albedo method. The albedo is defined as the ratio of 
absorption or scattering coefficient to the total attenuation coefficients.
The probability of photon absorption is given by:
P {absorption) = ———  (Eq. 2.10)
The probability of photon scattering is given by:
P {scattering) = ———  (Eq. 2.11)
Ma+Ms
where | i a is the absorption coefficient 
is the scattering coefficient
The angle at which the photon is scattered is calculated by using the Henyey- 
Greenstein phase function.1501
9  = —  v  (Eq. 2.12)
Ma + M, (l + g 2-2 co s^ )
The Lambert-Beer’s law is a simple process for estimating the light distribution but 
gives an inaccurate solution for a highly scattered medium when the scattering 
coefficient is much larger than absorption coefficient. This method is not suitable for 
wavelengths between 450nm and llOOnm where light is mostly scattered in the 
tissue.[51] Hence, the Lambert-Beer’s law is suitable for wavelengths below 300nm 
and above 1500nm where light is strongly absorbed and less scattered in the 
tissue.138,521
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2.1.3.2 Radiation Transport Theory
Another numerical method of describing the light distribution in the tissue is the 
radiative transport theory which is also called the Boltzmann Transport Theory. 
Chandrasekhar first used the Boltzmann Transport Theory to describe the rate of
where L{r, s) is the radiation intensity (watt per area per steradian) at position r in 
direction of s 
s is the direction unit vector
r is the position unit vector
(D is the solid angle
The first term of the right hand side in the above equation gives the decrease in 
radiation intensity per unit length L(r,s) by absorption and scattering. The second 
term gives the increase in the radiation intensity per unit length due to scattering 
from all other directions. The L(r,s')do)' term is the light radiance per unit area in 
direction s’ at a location r confined within solid angle dco'. The solid angle 
integration of phase function is defined a s t38]
The Boltzmann Transport Theory gives a more accurate description than other 
models but the general solution is not available. This method of analytical solution is 
only suitable for simple 1-D geometries. In the 2-D and 3-D problems, the numerical 
solutions are too rigorous mathematically and too complex to be solved analytically 
which require complex numerical methods. Another type of more simplified 
numerical solution is the Monte-Carlo method which will be described in Chapter 3.
change in radiance of light as a function of the optical properties of the medium.[53] 
The Boltzmann Transport Equation is described by1531
(S. V) L(r,s) = -<jla + n, )L(r , s)+ p(s,s' )L(r,s W  (Eq. 2.13)
(Eq. 2.14)
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2.1.3.3 Diffusion Approximation
When scattering becomes dominant over absorption, the intensity of scattered light is 
much larger than the collimated light in the tissue. The radiance of scattered light can 
be estimated by using an approximation of the transport equation.1541. This method 
assumes that the light is being scattered almost uniformly after encountering multiple 
scattering events.1341 The diffusion theory is defined mathematically b y [341
1 3
L (r ,s)  = — f L (r9s)do) + — f L {r,s)s*s dco (Eq. 2.15)
4 n i4x 4 n*4n
The first term of the right hand side in the above equation represents the isotropic 
scattering and the second term represents the forward peak compensation.
The diffusion approximation method is appropriate for dense and highly scattering 
tissue. Since the method requires diffuse light within the tissue, the diffusion 
approximation results are not accurate at surface layers and at boundaries. Hence this 
method is not applicable for thin tissues or tissues with multiple layers of optical 
properties and complex geometries. Also the accuracy of the results decreases as the 
anisotropy factor g approaches value of one for highly forward scattering tissue.1551 
As a simplified analytical method, it is only suitable for study of light diffusion deep 
within an optically uniform medium and it is easy to implement for computer 
simulations.f561 Analytical solutions can be obtained for 1-D geometries but 2-D 
geometries require a fast computer for numerical processing.1571.
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2.1.4 Effects of Light -Tissue Interaction
There are three main types of light tissue interactions namely photochemical, 
photothermal and photomechanical effects.
Photochemical effects are caused when the photons absorbed trigger off chemical 
reactions within tissue cells. Low energy light sources are mostly used for 
photochemical effects. The interaction time is considerable long and may range from 
minutes to hours. Photochemical effects are applied in the area of phototherapy, 
photochemotherapy, and photodynamic therapy
Photothermal effects take place when the photons absorbed by the tissue 
chromophores are converted to heat. The effects range from photothermolysis, 
photohyperthermia, photocoagulation, photocarbonisation and photovaporisation. 
The interaction time is short and range from milliseconds to seconds.
Photomechanical effects occur when the photons absorbed induce stress gradients 
and pressure waves to destroy tissue molecules. Photomechanical causes mechanical 
destruction of the tissue. The effects range from photoablation and photodisruption. 
The interaction time is very short. A Q-switched Nd: Yag laser can be used to provide 
the necessary power in short time for the breakdown of kidney stones in lithotripsy.
This study takes into account low energy interaction only and hence 
photomechanical interaction is not considered. The following review will concentrate 
on the photochemical interaction and photothermal interaction.
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2.2 Photothermal Interaction
2.2.1 Thermal transport in tissue
When a light source is used to illuminate through the tissues, photons are absorbed 
by the chromosphore structures in the tissues. Photon energy is transferred into the 
tissue and the heat is generated through the absorption of light. As soon as heat is 
created, it begins to dissipate by conduction, radiative transfer and convection. The 
basic law which apply to photothermal processes is the first law of thermodynamics. 
Thermodynamics is the application of the conservation energy principle to heat 
processes. The law states that the amount of energy gained by a closed system equals 
to the corresponding amount of heat lost by regions inside the closed system as 
defined by:
Qproduced Q  gained Q  stored + Qloa+ W  (Eq.2.16)
Q produced is the energy produced by the body metabolism
Q gained is the energy gained from the external source
Q stored is the energy stored in the body tissue
Q lost is the energy lost through conduction, convection, radiation
w is the rate of work performed by the body
The energy conservation in biological tissue can be represented by the Pennes 
Bioheat Transfer Equation (BHTE).[64] The BHTE is used to calculate temperature T 
as a function of time t and distance r from the source in the tissue. The equation is 
described by [64]
p c ^ °  = k V 2T ( r j )  - c hwb( T - T a)+ Q m+Qexl (Eq. 2.17)
where p  is the density of the tissue (kg • m~3)
c  is the specific heat capacity of tissue (J-kg~l -K~l)
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k  is the thermal conductivity (W • n f 1 • K ~l)
Qm is the rate of metabolic heat production 
Qext is the rate of external heating 
cb is the specific heat capacity of blood -K~l)
wb is the blood perfusion (kg • • s"1)
The first term kV2T(r,t) on the RHS represents the heat conduction in the tissue
while the second term -cbwb(T -T a) represents the heat removal by blood in
microvasculature. The perfusion term wb quantity varies with time to account for
collapse of the microvasculature perfusion during heating. The value of wb at any
location and time is dependent on the Arrhenius integral.1651 The Arrhenius integral 
Q is defined by1651
where is the frequency factor 
Ea is the activation energy
R is the rate constant for gas 
T is the temperature
The Arrhenius integral is used to describe the time-temperature behaviour for laser- 
induced thermal injury in the skin.[661 The Arrhenius intregral states that the rate of 
denaturation is exponentially related to temperature. Therefore the accumulation of 
denaturated material increases exponentially with temperature and proportionally to 
time. As a critical temperature is reached, coagulation occurs. The thermal 
coagulation of tissue has a sharp, threshold character which account for cell necrosis, 
haemostasis and bum injuries.
Most human cells can withstand prolonged exposure to 42°C. At 45°C, cultured 
human fibroblasts die after about 20 minutes. However, the same cells can withstand 
more than 100°C if present for only 10"3 seconds.1671 For exposure longer than 10'3
(Eq. 2.18)
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seconds at temperature above 42 °C as in hyperthermia application, the enzymes and 
other molecular components are affected and the structure of the membrane is 
loosened, causing denaturation and irreversible aggregation of macromolecules 
within the cell. This will lead to cell necrosis or cell death within 24 hours period. 
Hence, it is not temperature rise but a combination of light energy and exposure time 
that governs thermal damage. For most cells the critical temperature for necrosis
increases by approximately 10 °C to 20 °C for each decade decrease in the heating 
time.
Photocoagulation occurs at temperature above 60 °C which causes the denaturation 
of protein. Only a short exposure to high temperature is required and the effects are 
immediate and visible, such as tissue turning white. Hence it is a more obvious form 
of thermal injury than hyperthermia.
When the temperature in the tissue equal or exceed 100°C, the cell water starts to 
boil. The after shock of evaporation of water into steam causes the cell wall to 
rupture explosively allowing the steam to escape. Once the water has completely 
evaporated from the cell, complete rupture of tissue, also known as the popcorn 
effect, is observed.1681 The subsequent debris is rapidly raised to a higher temperature
up to 300 °C. When the 300°Cis reached, there is a further decomposition of the 
molecules which causes the tissue to turn black and become carbonised. At 
temperatures over 500°C , the remaining tissue will bum and evaporate.
There are many variables in photothermal interaction that need to be taken into 
consideration. The key characteristics to obtain the desired photothermolysis or 
photocoagulation are optimising the laser wavelength, pulse energy and pulse 
duration parameters.
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2.2.2 Laser parameters
2.2.2.1 Wavelength selection
The two primary factors which influence the choice of laser wavelength are the 
optical penetration depth of light in the skin and absorption of light by the target 
tissue chromophores. Light must pass through the epidermal and upper dermal 
regions of the skin to interact with the underlying tissue. In the visible light region of 
the spectrum, the skin has two main target chromophores; melanin and haemoglobin.
2.2.2.2 Pulse energy
A laser beam output with a Gaussian distribution is assumed to be incident on the 
skin. The laser irradiance L at point r (Wcm'2) is defined b y 1341
where P is the applied laser power (W) 
w02 is the beam radius (cm2)
The relationship between wQ and the laser wQ is shown in Figure 2.5 and is defined
(Eq. 2.19)
as [34]
(Eq. 2.20)
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Energy density L(r)
WO W i Beam radius
Figure 2.5: Gaussian beam intensity distribution of a laser beam.
The temporal output profile of a laser source is typically trapezoidal as shown in 
Figure 2.6.
300ps
Time300
Figure 2.6: Output power against time of a flash lamp pulsed dye laser.[70]
The laser energy E (J) delivered at point r is defined b y t34]
E (r ,t)= \TP d t  (Eq. 2.21)
Jo
where P is the laser power (W)
t is the laser exposure time (s)
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The laser fluence Et (Jem-2) is defined by1341
E ,= — % (Eq. 2.22)
7tWx
where E  is the laser fluence
7rwx is the area of beam spot size
2.2.2.3 Pulse duration
For maximum effectiveness of the laser pulse, the heat must be confined to the target 
tissue. In order to limit the thermal damage to the intended target tissue, the pulse 
duration must be shorter than the thermal relaxation time of the target tissue. The 
thermal relaxation time is defined as the time necessary for target tissue to cool down 
by 50% through transfer of its heat to surrounding tissue through thermal 
diffusion.[69] Table 2.1 shows the thermal relaxation time for different types of target 
tissue.
Tissue Type Diameter( pm ) T
Epidermis 60 2 msec
Basal layer 20 400 psec
Melanosome 1 0.2psec
Erythroctye 5 5|xsec
Table 2.1: Thermal relaxation time for different types of target tissues.
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The thermal relaxation time r  for a vessel is defined b y 1701
(Eq. 2.23)16a
where d  is the vessel diameter
a  is the thermal diffusivity
For small vessel applications, laser pulses shorter than the thermal relaxation time 
will generate maximum temperature rise and thermal damage in the vessel. Laser 
pulses that are equal to the thermal relaxation time will achieve the heat confined to 
the vessels, which allow a significant site-specific temperature rise and maximum 
thermal diffusion. Laser pulses longer than the thermal relaxation time will induce 
non-specific damage to the surrounding tissue through thermal diffusion. Table 2.2 
shows the approximate thermal relaxation time for vessels of different diameters.*481
Diameter (pm) r  (ms)
10 0.048
20 0.19
50 1.2
100 4.8
200 19.0
300 42.6
Table 2.2: Thermal relaxation time for vessels of different diameters.
If a target tissue can be heated sufficiently to affect it before its surrounding tissue is 
damaged by thermal diffusion, selective photothermolysis can be achieved.118,481 
Selective photothermolysis is based upon the principle of using laser energy to 
selectively injure a chromosphore target tissue while leaving the healthy surrounding 
tissue structures unharmed. The principle is therefore to irradiate the skin with a 
suitable wavelength light source which only the energy are absorbed in the target 
tissue and the light are passed through the epidermis and dermis. It is by far the most
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precise use of heat in medical application. This selective photothermolysis theory 
le\d to the development of flash lamp pulsed dye lasers which have been very 
successful in treating port wine stain and in wrinkles reduction.
Table 2.3 below lists the current laser technology for photothermal application.[701
Laser Type Wavelength Pulse duration Output
Flash Lamp Pulsed Dye 
Laser
585nm 200-450 ps 20J/cm2
Argon Laser 488nm&
511nm
0.1-1 s 3-10W 
Average power
Copper Vapour Laser 577nm 50ns@10-
15khz
1-5W
Table 2.3: Types of lasers and the light output specifications.
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2.3 Photochemical Interaction
Photochemical interaction is applied mostly in the therapeutic medicine. The 
photochemical effect within the tissue can occur as phototherapy, 
photochemotherapy and photodynamic therapy. The relationship between three types 
of photochemical reaction is shown in the following Figure 2.7. Phototherapy is a 
general term used to describe all cases where light is used therapeutically; 
photochemotherapy is a subset of it, and photodynamic therapy is a subdivision of it.
PDT
PHOTOTHERAPY
PHOTOCHEMOTHERAPY
Figure 2.7: Venn diagram of photochemical reaction.
2.3.1 Photochemical Laws
The definitions of each photochemical effect are described as follows:1711 
Phototherapy
The use of ultraviolet, visible, or near infrared light in the treatment of disease. In 
cases where no photosensitiser is administered the light is absorbed by 
chromosphores present in the tissue. E.g. photogeneration of collagen.
Photochemotherapy
The use of ultraviolet, visible, or near infrared light together with an administered 
photosensitiser in the treatment of disease. Light is absorbed by the photosensitiser. 
E.g. PUVA therapy of psoriasis.
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Photodynamic therapy
The treatment of disease by the use of visible or near infrared light together with an 
administered photosensitiser and in the presence of molecular oxygen at ambient 
levels. Light is absorbed by the photosensitiser, which then serves to activate oxygen. 
The activated oxygen then causes damage to the living system.
The three important basic laws which apply to photochemical process are t?1]
Law 1 - Grotthus-Draper Law
The Grotthus-Draper Law states that only light which are absorbed by a system can 
cause a photochemical change. If no photons are absorbed, no photochemical 
reaction can occur.
Law 2 - Stark-Einstein Law
The Stark-Einstein Law states that the absorption of one photon excites one substrate 
molecule in the initial excitation step of a photochemical reaction. The quantum yield 
cannot be greater than 1.
Law 3 -  Bunsen-Roscoe Law
The Bunsen-Roscoe Law states that the photochemical effect depends on the total 
dose (intensity x time) and not just the dose rate (intensity).
The main focus of this study is on photodynamic therapy and hence phototherapy 
and photochemotherapy will not be reviewed here. Photodynamic therapy is a 
photochemical process that is dependent on the fluence and fluence rate of the light 
source as well as the oxygen concentration and photosensitiser concentration in the 
tissue. There are many variables in photodynamic therapy that need to be taken into 
consideration. Figure 2.8 shows the schematic diagram for the PDT steps. Each step 
has its own variables and is highly dependent on other process. The two most 
important parameters that influence the photodynamic therapy results are
• Photosensitiser
• Light
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Oxidative Damage
Singlet Oxygen 
Radicals
Sensitiser Drug
Light Source
Activated Drug
Oxygen
£
Cell Death
Figure 2.8: Schematic diagrams of photodynamic therapy steps
2.3.2 Photosensitiser parameters
An ideal photosensitiser suitable for PDT should have the following attributes:t71,72]
• Have a strong absorption at a longer wavelength where tissue penetration 
depth is at a maximum
• Preferentially drug localisation to target tissue
• Have a high quantum yield for efficient singlet-oxygen generation
• Have a minimal dark toxicity and only cytotoxic with light activation
• Rapidly excretion from the body thus inducing a low systemic toxicity
44
2. Light- Tissue Interactions
2.3.2.1 Absorption wavelength
The transmission of visible light through human tissue is dependent on the 
wavelength of the light. At the blue region of the visible spectrum, the absorption 
and scattering by melanin and oxyhaemoglobin are at their greatest. Both factors are 
much lessened in the red region of the visible spectrum. For maximum optical 
penetration depth of light into tissue and efficiently absorption, the photosensitiser 
needs to have a high absorption band in the region of 650-750nm.
Photofrin® has a high absorption peak in the 400nm-450nm region but it is not 
suitable for use due to high absorption peak of melanin in the blue region. Hence in 
order to achieve deep penetration of light into tissue, a wavelength of 630nm is 
usually used for activation. The absorption of Photofrin® at 630nm is a minimum 
level, thus requiring a higher dose concentration of photosensitiser. Figure 2.9 shows 
the absorption spectrum for various types of photosensitisers and Table 2.4 shows the 
characteristics of photosensitisers currently in clinical application.
Metallophythalocyanines (AlClPc) exhibit very high absorption peaks in the near UV 
region and the red region. The difference in absorption between AlClPc and melanin 
is significant in the red region and hence this region is the suitable wavelength choice 
for photodynamic therapy. Temoporfin (m-TMPC) has the highest absorption peak 
among the six photosensitisers in the blue region. If an embedded light source is 
used, the absorption in the melanin could be reduced or ignored, therefore greatly 
increasing the absorption of the photosensitiser in the blue and red regions. This 
method will increase the efficiency of singlet-oxygen generation and have a better 
PDT response. In effect, the photosensitiser dosage and the light dose can be reduced 
with the increased rate of singlet-oxygen production.
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Figure 2.9: Absorption spectrum for various types of photosensitisers 1331
Photosensitiser Activation
wavelength
(nm)
Dosage
(mg kg ')
Time
post-injection
Photofrin® 630 2.0-5.0 24-48h
ALA 635 <30 (intravenous) not available
Tin etiopurpurin 660 1.0-2.0 24h
Temoporfin (m-THPC) 652 0.1-0.3 24-48h
Texaphyrins 632 0.6-7.2 3-5h
Table 2.4: Characteristics of photosensitisers currently in clinical application 1141
—  SnET2 100 ug/ml
—  Photofrin 37.5 ug/ml 
mTHPC 5.0 ug/ml
—  Chlorine e6 5.0 ug/ml
AlClPc
BPD
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23.2,2 Tumour selectivity
There are two main objectives in achieving tumour selectivity.
1) To reduce damage to the normal adjacent tissue, since the area surrounding 
the tumour will receive some irradiation during photodynamic therapy.
2) To reduce long term general photosensitivity.
The localisation of the photosensitiser is described by its concentration in various 
tissues with respect to time and location in the biological system. The timing of the 
administration of photosensitising drug relative to the time of irradiation is the key 
parameter in determining the localisation and the tumour uptake of the drug. The 
minimum post-injection time required for maximum tumour uptake of various 
photosensitisers is listed in Table 2.5. Most photosensitisers are found in high 
concentration in the metabolically vigorous tissues especially liver, spleen, kidney 
and lung.
One of the particular considerations is the ratio of photosensitiser in tumour cell with 
respect to concentrations in all the other tissues at the time of illumination. Secondly, 
it is desirable that the photosensitiser has zero or very low cytotoxic in the absence of 
light during the post-injection period. This mean the tumour photodestruction can be 
efficiently controlled by the light dose for a given drug dose. Table 2.5 shows the 
ratio of photosensitiser drug uptake into the tumour and surrounding or remote 
normal tissues.
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Species Drug (route, 
dose in mgkg"1)
Tumour/normal tissue (Time)Ratio of uptake
Hamster Photofrin pancreas ca(in situ)/ (3h)
(i.v.,2.5) liver
pancreas
ileum
0.3:1
2.3:1
0.8:1
Rat HPD colon ca (in situ)/ (72h)
(i-P-, 10) colon 1.8:1
Rat Photofrin bladder lesions(/« situ)/ (lOOh)
(5) bladder hyperplasia 
non-invasive ca 
invasive ca
1.3:1
2.0:1
3.5:1
Mouse HPD colon ca (s.c.)/ (48h)
(i-v.,27) liver
skin
0.1:1
1.7:1
Mouse HPD bladder ca(s.c.)/ (3h) (48h)
(i.t., 0.4 mg/ hver 8.9:1 15:1
ml tumour) skin 101:1 55:1
Man HPD colorectal adenoca(in (3h)
(i.v.,2.5) situ)/ normal mucosa 8.2:1
Man HPD glioblastoma(i.c.)/ (24h)
(i-v.,5) BAT region 
normal brain
0.9:1
35:1M
Mouse mTHPP astrocytoma(i.c.)/ (24h)
(i-v.,34) normal brain 100:1
Mouse Various drugs mammary ca(s.c.y hver (drug) skin at 24h
(i-P-,25) hver and skin 0.3:1 Photofrin 2.3:1 
1.2:1 3THPP 3.3:1 
1.1:1 TPPS4 1.7:1 
1.1:1 Chi e6 4.8:1 
0.1:1 A1PCTS 1.9:1 
0.1:1 A1PC 1.0:1
Mouse Chi e6 sarcoma of kidney(s.c)/ (48h)
(i.v. 200) liver and skin 6.3:1
Table 2.5: Ratio of photosensitiser drug uptake into the tumour and surrounding 
normal tissues[73]
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Mouse AlPCTrS 
(iv, 10)
colorectal ca (s.c.)/
liver
colon
skin
(24h)
0.2:1
7.0:1
5.7:1
Rat AlPCTrS fibrosarcoma (s.c.)/ (48h)
skin 0.9:1
Rat A1SPC colon ca (in situ)/ (48h)
colon 2.2:1
Table 2.5 (Continued)
2.3.2.3 Singlet oxygen generation
The photodynamic effect is mediated largely by the generation of singlet excited 
oxygen. The singlet oxygen is estimated to have a short lifetime (3-25ps) and can 
diffuse about 0.01pm.1731 Hence the primary damage can only be initiated in the 
immediate vicinity where the photosensitiser is located. The photochemical 
efficiency in which various photosensitisers generate singlet oxygen is the singlet 
oxygen quantum yield. Since singlet oxygen generation is a key intermediate in 
photodynamic therapy, the importance of quantum yield of singlet oxygen formation 
<|>Amust be considered. A value of more than 0.3 for <|>A is desirable to be used as an 
effective photosensitiser. Table 2.6 presents the values of quantum yields of singlet 
oxygen <|>A and triplet quantum yields <|>T for various photosensitiser compounds.
Photosensitiser type Solvent 4>a
Protoporphyrin dme PhH 0.57 0.80
Haematoporphyrin MeOH/H20 0.65 0.83
Uroporphyrin H20 0.52 0.93
m-THPC MeOH 0.43 0.89
TPP PhH 0.63 0.67
Photoprotoporphyrin dme PhH 0.67 0.65
Bacteriochlorophyll a PhH 0.32 0.32
Porphycene PhMe 0.30 0.42
Table 2.6: Triplet quantum yields <|>Tand singlet oxygen quantum yields <|>A 
production of various photosensitisers[71]
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2.3.2.4 Photobleaching
The term photobleaching refers to the breakdown of photosensitiser as a result from 
exposure to light irradiance that leads to chemical changes in the photosensitiser. The 
chemical changes results in small fragments which no longer have significant
I absorption in the visible region. In an in vitro study, protoporphyrin IX generated
from 5-ALA photosensitiser is rapidly photobleached in cells with 70-95% of 
protoporphyrin IX degradation at light fluences of 40-200 Jem'2 at 630nm.[74] Table 
2.7 shows the values of photobleaching quantum yields (J)^  of four different
l!
| porphyrins at 25 °C .After a photodynamic therapy treatment, some residual part of
the photosensitiser located in the normal tissue would be subject to photobleaching 
under ambient light conditions, thus reducing the period of photosensitivity.
Types of porphyrin Photobleaching quantum yields ((J)^)
Haematoporphyrin 4.7 x 10‘5
Uroporphyrin 2.8 x 10'5
TPP 9.8 x 10-6
Photofrin 5.4 x 10'5
Table 2.7: Photobleaching quantum yields of four different porphyrins[75J
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2.3.3 Light parameters
2.3.3.1 Wavelength selection
A basic consideration in the efficacy of PDT treatment is depth of penetration of 
light through the tissue. In the choice of wavelength for photodynamic therapy use, 
two factors apply:
1) The exact wavelength selection will depend on the absorption characteristics 
of the photosensiter drug. The wavelength used should match the peak 
absorption of the photosensiter for maximum light activation of 
photosensitiser drug.
2) Light should be able to reach the tumour cell located deep in the tissue and 
generally longer wavelengths of visible light penetrate tissue more efficiently 
than shorter wavelengths. There is strong attenuation of light from 400nm up 
to 580nm largely because of high absorption of melanin and haemoglobin in 
this region. At 600nm to 680nm, there is a rapid rise in penetration depth due 
to the low absorption by haemoglobin. The penetration depth increases 
gradually between 700nm to 800nm.
By taking into the account the above factors, the suitable range of wavelength for 
photosensitiser selectivity is located in the red region. Therefore 630nm is the 
preferred choice of wavelength for most PDT applications.
2.3.3.2 Fluence rate
For photodynamic therapy, three important quantities that govern light exposure are 
total light dose, fluence rate of light source, and exposure time. The relationship 
between these quantities is as follows:[71]
Total light dose (J-cm~2) x 1000 
Fluence rate at treatment site (J • s'lcm'z)
Exposure time(seconds) = -  x ,2n (Eq. 2.24)
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The PDT light dose to be used for treatment depends on the type and dose of 
photosensitiser. Low fluence rate has been shown in many studies to cause the same 
damage to tumour cells and highly enhanced the photodynamic efficacy compared to 
high fluence rate.[76’77,78,79,80’81] One of the reasons is that oxygen concentration in 
tissues decreases during high fluence PDT which leads to oxygen depletion.1821 Low 
fluence PDT lowers the rate of oxygen consumption, thus increasing the oxygenated 
region in the tumour. Oxygen level does not get depleted to the threshold level 
required for photodynamic actions and the production of singlet oxygen is not 
interrupted during the low fluence rate treatment. Another reason is that high fluence 
rate decreases the photodynamic effectiveness by limiting the photodynamic 
damage.1801 The photodynamic damage may reach saturation point which depends on 
the photosensitiser concentration. It is possible that, due to the much lower efficacy 
at saturation fluence levels, photobleaching would prevent administration of a 
photodynamic dose sufficient for complete tumour kill.1771 Therefore low fluence rate 
treatments can be as effective as high fluence rate treatments for the irradiation 
applied over the same period of time.
2.3.3.3 Fractionation of light
Studies have shown that fiactionation of light was much more effective in cell killing 
compared to continuous light applied at the same power density. I76*77*78 83*84! This is 
because fractionation of light lowers the rate of oxygen consumption and the cell is 
reoxygenated during the short recovery time which leads to more cytotoxic effect 
due to greater activation of singlet oxygen. Muller et al have demonstrated that light 
fiactions of only 0.05 s can improve PDT significantly.1851 A theoretical study by 
Pogue et al suggests that the optimal fractionation time is dependent with the 
distance between capillaries and cells and varies between 30 seconds and 60 
seconds.[861 In addition, some residual tumour cell might be reoxygenated to normal 
level at 24 hours after first irradiation and recovery of damaged cells occurs at 48 
hours later.1871 Fractionation interval of irradiation subsequently 24 hours after first 
irradiation greatly enhanced the photodynamic effect.
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CHAPTER 3 COMPUTER MODEL
In order to understand how light interacts with the tissue, a computer model named 
TODDY has been developed to simulate the laser-tissue interaction in two dimensions 
(2-D), The computer model is based on a three-stage process.
For the first stage, a radiation transport solver is used to generate a fluence map of the 
tissue sample. The fluence map produced shows how light was distributed throughout 
the tumour site.
In the second stage, a thermal solver is used to produce a time-dependent thermal 
profile of the irradiated site.
The third stage of die model used a photochemical solver to generate a photodynamic 
damage profile of die tissue model. The photodynamic damage profile produced an 
estimate of the damage at every location in the tissue, especially the tumour site.
3.1 Light Transport Algorithm
An analytical solution of transport equation that describes the light distributions in the 
tissue is not available. Although diffusion approximation theory and Lambert Beer 
law have been used to calculate light flux distributions in a simplified model, these 
methods are not suitable to model light transport in the skin with complex geometries 
and heterogeneous structures. An alternative numerical solution to the transport 
equation is the probabilistic technique called the Monte-Carlo method.
The Monte-Carlo method involve the generation of random numbers within a 
predetermined range to simulate various processes that occur in the problem. In laser- 
tissue problems, the method may be used to randomly select individual photon 
scattering angles and path lengths. Cashwell and Everett were the first to establish the 
weighting method in the Monte-Carlo simulation for neutron transport in the field of 
nuclear reactor.1891 Wilson and Adam reintroduced the weighting method later in 1983 
to improve the simulation’s efficiency of light transport in the laser-tissue
53
3. Computer Model
interaction.t901 This method models the light transport in the tissue by considering the 
statistical average effect of a very large number of photons.
The advantages of using the Monte Carlo method is that it provides a simple solution 
to a problem with complex geometries and gives a reasonable accuracy comparable to 
die general transport theories. It also gives more accurate results near to surfaces and 
near to die collimated laser beam than the faster diffusion approximation.t91J
3.1.1 Two Dimensional Model
The human skin consists of multiple layers with each layer having different 
absorption and scattering coefficients. Hie skin-tumour model is represented by a 
simple two-dimensional, multi-planar structure which includes epidermis, basal layer, 
dermis and tumour as shown in Figure 3.1. The light source can be placed outside the 
skin for surface irradiance or embedded into the skin for subcutaneous irradiance. In 
this model, there are three assumptions being made. The light is assumed to irradiate 
perpendicularly incident into the skin thereby reducing the amount of light lost 
through reflection at the air-skin boundary. Secondly, the optical properties o f tissue 
are assumed to be constant and independent of temperature changes. Thirdly, the 
tumour contains mostly blood vessels and the blood vessels chromophore is 100% 
oxyhaemoglobin which is homogeneously distributed in the vessels.
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Light
 ►
 ►
 ►
Epidermis Tumour Dermis
Figure 3.1: Skin-tumour model represented as parallel plane layers.
The skin-tissue model is represented as a two dimensional array of cells which uses a 
Cartesian grid system with spatial position (x,y) as shown in Figure 3.2. Each cell has 
its own absorption and scattering coefficient depending on the type of tissue. As the 
2-D model is assumed to be infinite in the z direction, the volumetric photon energy is 
calculated and stored in an array called ‘numabs[i][j]’ for all values of i and j from 0 
to imax and jmax where i and j are the values that represent the depth and width of the 
virtual tissue sample.
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Figure 3.2: Two dimension Cartesian grid system representing the skin-tumour mode .
Photons are launched at the skin boundary or at an internal point in the tissue and their 
paths through the tissue are tracked and recorded. The initial position of photon’s 
launch can be varied to accommodate the starting point of embedded light source. 
Each photon is initially assigned a weight (Wo) equal to unity. A photon can be 
scattered or absorbed at each interaction. The probability of this photon being 
absorbed or scattered is dependent on the albedo as the weighting factor.[56]
u,
The probability of photon absorption is given by: ---- 5—
P a + P s
The probability of photon scattering is given by: ---- 5—
Pa+Ps
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The propagation of each photon is selected from an exponential distribution using a 
computer generated pseudo-random number. The path distance that a photon travels 
between successive interactions is given by [56J
where R is a pseudo-random number between 0 and 1.
A photon in any given cell can be scattered into any one of eight direction cells as 
shown in Figure 3.3. The direction of photon scattering is calculated by generating 
another random number and applying it in the probability density function. Hence, the 
angle of scattering is determined by using the Henyey-Greenstein phase function.
Figure 3.3: Possible photons scattering directions in one of eight direction cells. 
The angle of scattering,#, given by Henyey-Greenstein phase function is described
l = - h v
Ma+M,
(Eq.3.1)
Backward
Scattering
Forward
Scattering
by'56'
(Eq. 3.2)
where R is a pseudo-random number between 0 and 1.
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The new position of the photon is determined by the path length and the angle of 
scattering. At each interaction, a fraction of the photon’s energy is being absorbed and 
the rest is being scattered. The photon will continue to scatter and reduce its energy 
until the energy falls below a given threshold value.
At each interaction point, a fraction (jua / jut) of the energy of the current weight, Wj, is 
deposited at the cell, The energy decreases due to multiplying it by the weight 
(jus / //,) at each interaction as shown in Figure 3.4. The fraction of energy absorbed
and scattered at the each i interaction point are Di and Wi respectively. The photon 
weight is updated following each scattering event.
Tissue surface
i-l
Figure 3.4: Schematic diagram of photon path in the tissue.
A new propagation path for the next photon will begin when the photon is either 
completely absorbed, its weight fallen below a threshold level, or escaped the tissue. 
The whole process is repeated for every single photon used in the simulation. The 
photon energy deposited at each cell is accumulated in order to map out the 
distribution of light absorption.
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A volumetric distribution of energy absorption is then obtained for each cell by 
dividing the deposited photon weight in that cell by its volume and by the total 
numbers of photons propagated. Since the 2-D model is assumed infinite in the z 
direction, each cell’s volume is obtained by multiplying its surface by the unit length 
in the z direction.
The total number of photons required for propagation depends on the accuracy needed 
and the spatial and temporal resolution for the model. After the entire photons have 
been deposited, the distribution of light absorption will be known and mapped out. 
This volumetric distribution of photons energy is taken as a fluence source and can be 
used in the numerical model of the photothermal and photodynamic damage to 
compute the tumour damage in response to light irradiation in the tissue.
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3.2 Thermal Transport Algorithm
Heat transfer in the tissue occurs mainly through conduction, convection and blood 
perfusion. Heat conduction in tissue is the dominant factor in this study of thermal 
transport. There is no cooling of skin surface used hence convection process is not 
considered in this study. The amount of heat transferred by blood perfusion varies 
during irradiation. The bioheat transfer equation includes the heat conduction and heat 
source.
Heat conduction at a position (x,y) is given by11051
where T is the temperature at point r
Q is the heat source term (Wm'3) 
k is the thermal conductivity (Wm'1 °K’1) 
a  is the thermal diffusivity of the tissue(m2s'1)
The thermal diffusivity is given b y [105]
where k is the thermal conductivity (Wm'1 °K'1) 
pC is volumetric heat capacity (Jm-3 °K'1)
To solve the equation 3.3, a numerical solution based on the well-known Finite 
Difference method is used.
3.2.1 Finite Difference Method
To model the heat conduction in tissue, a two dimensional conducting region with the 
same thermal properties across the region is used. The conducting region of interest is
J_ ST(x,y) _  82T g2T Q 
a  St Sx2 Sy2 k (Eq. 3.3)
a  = k/pC (Eq. 3.4)
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represented by a regular 2-D Cartesian grid system, where the grid spacing is Ax and 
Ay, as shown in Figure 3.5.
Ax
Figure 3.5: Cell point Py in the 2-D Cartesian grid with uniform grid spacing.
The basic concept of the Finite Difference method is to substitute the derivatives in 
the differential thermal diffusion equation by forward, backward and central 
differences according to Taylor series expansion. If the initial and boundary 
conditions are known, the differential equation can be organised into sets of algebraic 
equation. There are two types of finite difference are available namely the explicit 
method and implicit method.
3.2.2 Explicit Method
The explicit method allows the temperature at a given point at a new time level 
(t + At) to be calculated explicitly from the temperature at nearby points at time t. This 
requires the first-order partial derivative (LHS of equation 3.3) to be evaluated using a 
forward difference representation involving T(t + At) and T(t) or by truncating the 
Taylor series expansion to obtain an estimate of error. The new LHS arrangement is 
written a s [105]
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(Eq. 3.5)
where i j  subscripts represent the position
n,(n+l) superscripts represent the time (t) and (t + At) respectively 
At is the time step
O(At) indicates the truncation error term. The truncation error is of order At, 
in order to provide a stable numerical method
In order to estimate the second-order partial derivatives in space (RHS of equation 
3.3), two Taylor series expansions are added at time t. The new RHS arrangement in 
each direction is written a s11051
A Fourier number, F0, is used in unsteady state heat transfer calculation. The Fourier
Number describes the rate at which a body will respond to a temperature change and 
is essentially a function of the physical geometry and thermal characteristics of the 
cell. The time steps chosen for each point to determine the temperature in the cell 
must meet the Fourier Stability criteria.. The Fourier number is given b y [105]
where a  is the thermal diffusivity
(Eq. 3.6)
where h is the cell size
o (h 2) indicates the truncation error term which is of order h2
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A restriction is placed on the Fourier number from which the matching time step can 
be obtained in order to keep the numerical method stable.
F0 < 0.25 in 2-D Cartesian problems 
F0 < 0.5 in 1-D Cartesian problems
Substituting equation 3.5 and equation 3.6 into equation 3.3 gives[1051
1 X“i+1- T “j Tn. -  2T“ + T". T“ -2 T in+Tn1 Qn
H  J  J )=  Hl - d   ‘r  + J . 2 ------- + ^ ~  (Eq. 3.8)a  At h  h  k
where ij  subscripts represent the position
n,(n+l) superscripts represent the time (t) and (t + At) respectively
Multiplying by h2 and inserting F0 in the equation 3.8 gives
1 y n + l _ rr,n , rr,n i T n i T n _
u ij i+1 j i-1 j ij+1 ij-1
Ao
n
(Eq. 3.9)
The temperature at each point Py of the Cartesian grid can be obtained by solving 
equation 3.9 when the initial and boundaiy conditions are known. Although the results 
obtained with the explicit method are accurate, the Fourier restriction leads to very 
small time steps which require very long simulation times. A much quicker approach 
can be obtained by using an implicit method with larger time steps and coarser grid 
spacing.
3.2.3 Implicit Method
In an implicit method, the temperature at a given point at a new time level is obtained 
from temperature at nearby points at that new time levels. The first-order partial 
derivative in time is obtained by truncating the Taylor series expansion. The second- 
order partial derivatives in space are estimated by adding the two Taylor series 
expansions at time(t + At). Rewriting the equation 3.3 at time(t + At) gives[1051
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T n + l_ T n  T n+1 Axn+1 ,T n + l Tn+1 _  O jn+1 , yn+1 t
1 ^ ) -  i+l \  i-1 | J+1 \  j - 1 , Q__
h 2a  At h 2
where i j  subscripts represent the position
n,(n+l) superscripts represent the time (t) and (t + At) respectively
(Eq. 3.10)
Multiplying by h and inserting Fc in the equation 3.10 gives
1 T n — T n+1 i T n+1 _u T n+1 _i_Tn+^ _  
p  ij i+l j  i-1 j  ij+1 ij-1A A
f  1 '  
4 + r ,o ;
It is observed from equation 3.11 that no restriction needs to be placed on the Fourier 
number and larger time steps can be used. Since the temperatures at the new time 
level cannot be directly computed from previous known temperatures, the 
temperatures are obtained by solving for each time step, a set of simultaneous 
equations coupling the new temperature at the neighbouring points. In a 1-D problem, 
the linear system can be solved rapidly using matrix algorithms. However in a two 
dimensional problem, no rapid solution can be used and an iterative method has to be 
applied. This could increases the simulation time even though implicit method is 
faster than the explicit method. The other numerical methods used to solve this 
problem are the Crank-Nicholson method and the alternating direction implicit (ADI) 
method. The ADI method was used in the thermal model.
3.2.4 ADI Method
Another way of solving the thermal diffusion equation is the use of alternating 
direction implicit method. The basic of ADI method is to express the derivatives into 
two half steps. For the first half step, the derivative is expressed in one space direction 
(x) implicitly, and the other direction (y) being expressed explicitly. In the second half 
step, the direction for implicit representation is changed. The diffusion equation is 
written in tridiagonal matrix form. This matrix form requires only one set of rows or 
one set of columns to be solved at iteration. The tridiagonal matrix algorithm is 
applicable and solutions are obtained rapidly. Nevertheless, this method is much more 
complex to code than the fully implicit method but the simulation time could be 
reduced significantly, since it is half-implicit with the full implicit method stability.
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The temporal profile model of a light pulse is represented as a simple functional form 
as shown in Figure 3.6. This consists of rise, hold and fall time which can be varied 
while maintaining the delivered energy constant. The beam pulse width is divided into 
a number of strips of width equal to the time step to create the time bands. The 
photons are distributed evenly between the time bands and the model steps through 
the temporal profile of the beam pulse with a time step less than the Fourier Number.
Time
Fall
Time
Hold
Time
Rise
Time
Figure 3.6: Temporal profile model with rise time, hold time and fall time.
The temperature in a given cell at given time is determined by the following process:
a) The proportion of the total energy in the pulse delivered during the time step is 
calculated. This takes into account the temporal profile of the light pulse.
b) The cell in matter only receives a fraction of the pulse energy, the value being 
determined from the result of Monte Carlo simulation. The absorption of 
energy produces a direct heating effect on the particular cell.
c) The temperature in the given cell has a contribution from the adjacent cell. 
This can either be a positive or negative heat effect.
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The temperature calculation required steps are represented graphically in a schematic 
diagram as shown in Figure 3.7. These procedures are repeated for the entire duration 
of the light pulse to determine the temperature profile in the skin and tumour cells.
Total Pulse 
Energy
I
Proportion of 
Energy in Time 
Step
Energy Directly 
Absorbed in 
Cells
Adjacent Energy Gained Adjacent
Cells «----- ► or Lost to *----- ► Cells
Adjacent Cells
Figure 3.7: Procedures in determining the temperature rise in the cells.[70]
Taking into the account of all the factors for the calculation of the temperature in the 
cell, the cell temperature is given as
r r r  ~\
Heat generated from + Heat from Heat lost during
direct absorption adjacent cells time step
V J L  J L  J
The thermal model was developed to display the temperature variation of any cell at 
any time during the pulse period.
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3.3 Chemical Transport Algorithm
3.1 Oxidative Damage Method
The photodynamic damage factor is introduced to quantify the amount of damage 
produced by oxidative interactions leading to photodynamic therapy. It is assumed 
that the rate of photodynamic damage occurring at time t is proportional to the fluence 
rate and the local concentration of photosensitiser and oxygen at that time. Another 
assumption made is that all biological damage is singlet oxygen mediated by only the 
Type II reaction.
The photodynamic damage occurring within a cell in tissue at time t is defined b y [78]
where kpd is damage rate constant 
I{t) is the fluence rate 
P{t) is the photosensitiser concentration 
0 2(t)is the oxygen concentration
The photodynamic damage constant kD value combines the photosensitiser 
absorption coefficient and the efficiency of generation of cytotoxic oxygen species.
The total fluence E  delivered at a cell in tissue with time t is defined b y f78]
(Eq. 3.12)
(Eq. 3.13)
where I{t) is the fluence rate
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The photosensitiser concentration P in a cell in tissue at time t is defined b y l78]
= X n O )x  dt (Eq.3.14)
where k is the photosensitiser production rate constant 
is the photobleaching rate constant 
I(t) is the fluence rate
P(t) is the initial photosensitiser concentration 
0 2{t) is the initial oxygen concentration
The model assumed that there is no photosensitiser formed during irradiation, hence 
photosensitiser production rate constant is zero. The photobleaching rate constant 
kPB is wavelength dependent as light absorption is required.
The oxygen concentration O2  in a cell in tissue with time t is defined by1781
O2(0  = (*petf- * <» J « W ) x < *  (Eq. 3.15)
where is the tissue perfusion rate constant 
k is the oxygen removal rate constant 
PD{t) is the rate of photodynamic damage at time t
The on the RHS is for the supply of oxygen to the tissues and is assumed to be
net perfusion over metabolic processes. The second term represents the rate of 
removal of oxygen by photodynamic processes is proportional to the amount of 
photodynamic damage occurring at that time.
68
3. Computer Model
Macroscopic damage to the tumour in photodynamic therapy could occur by two 
possible pathways:
1. Direct damage to tumour cells
2. Damage to endothelial cells of the vascular system and around the tumour 
thereby shutting off its blood flow
The death of the tumour cells occur by two distinct modes:
• Necrosis
• Apoptosis
Necrosis takes place when the membranes or other vital units are mostly damaged so 
that the cells can no longer sustain essential function and die. This type of destruction 
occurs quickly.
On the other hand, apoptosis is programmed cell death and it may take 24 hours for 
the program to operate and kill the cell. The apoptosis may be recognised by various 
biochemical markers, for example the fragmentation of DNA in the cell and 
mitochondrial changes. Kessel et al reported that two photosensitisers, which are 
located in the lysosomes, rapidly initiate apoptosis leading to cell death.[88J
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CHAPTER 4 REMOTE COUPLING OF POWER
The embedded light source proposed for the photodynamic therapy application 
requires an efficient energy source to power the LED. Several possible methods to 
power the LED have been considered including the use of remote coupling. All of 
the methods have their inherent practical difficulties in the implementation.
The use of a battery is the simplest way of supplying power to the LED. The 
disadvantage is that the size of the device will increase considerably that it is no 
longer small in size to be embedded into the tissue. Furthermore, a battery has 
limited power and need to be removed from the tissue and disposed once the power 
runs out; hence the device has limited lifespan usage. A battery also contains toxic 
nickel or lithium materials which are harmful if accidentally leaked into the tissue.
An alternative way of supplying energy to the LED is through the use of remote 
coupling. This method utilises either radio frequency (RF) or microwaves as the 
coupling and energy transfer medium. The mechanism of energy transfer is through 
inductive coupling for l-30MHz region and radiative coupling for lOOMHz-lOGHz 
frequency region. The remote coupling RF system consists of
• Transmitter - RF generator
• Receiver -  RF device
The RF device is a passive device, which it does not require any internal power 
source. This has positive implications on the cost, life-time and environmental 
situation. The necessary power required to energise and activate the RF device is 
drawn from the localised electromagnetic field.
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The two primary factors which influence the choice of the frequency for remote 
coupling are:
a) How much o f the energy is lost or attenuated in the tissue?
b) How does the frequency affect the penetration depth o f the waves in the tissue?
Once an ideal frequency has been selected, a third and highly significant issue that 
must be solved is
How could the energy be coupled into a small antenna receiver efficiently?
An understanding of the electromagnetic waves and the tissue dielectric properties 
are required in order to achieve maximum efficiency of energy transfer into tissues.
4.1 E.M. Waves Propagation in Tissue
For this study, it is assumed that all electromagnetic waves are transmitted as plane 
waves to describe the propagation of waves into a tissue. The use of plane waves is a 
good approximation to the actual system and a useful mathematical description 
because it simplifies the analysis of electromagnetic waves.
The propagation of electric and magnetic fields is described by the differential form 
of the complex time-harmonic steady-state Maxwell's equations. The Ampere’s law 
of static magnetic field is one of the Maxwell’s equations and is defined by [94]
V x H  = J+j<oe0srE  (Eq. 4.1)
where H  is the complex vector of magnetic field intensity 
E  is the complex vector of electric field intensity 
a) is the angular frequency 
eQ is the permittivity of free space 
er is the relative permittivity of medium
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The electric field of the incident plane wave, E  generates a current density J [94]
J  — &E (Eq. 4.2)
where <r is the conductivity (S/m)
Substituting equation 4.2 into equation 4.1 gives
V * H  = j(D£0€r
r \
1 - y  —
V 0 )8 oe r )
(Eq. 4.3)
The complex permittivity £d is defined a s [94]
ed =e +je  =er - j . <7
Cd£„
(Eq. 4.4)
where er is the real part of 8d and is equal to relative permittivity er 
e is the imaginary part of 8d and is equal to -<j I co£0
The equation 4.3 can be rewritten as
V * H  = jCO£Q£dE (Eq. 4.5)
For propagation in a homogeneous dielectric medium, the plane wave expressions 
for E and H will include a propagation constant.
The propagation constant y is defined a s [94]
r  = a+J0 (Eq. 4.6)
where (3 is the phase constant of medium
a  is the attenuation constant of medium
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The solution for plane waves in a dielectric medium is given b y [94]
E - E 0 exp[j(wt -  fiz)] exp[-az] (Eq. 4.7)
The above solution shows that the plane waves have a sinusoidal part and an 
exponential part whose magnitude decays as either a  or z increases.
4.1.1 Characteristics of Plane Waves
The plane waves transmitted in the air are normally incident on a tissue to the 
boundary of the tissue. A plane wave is a wave where there are spatial variations 
only in the direction of travel. The path of travel is in the z direction into the tissue as 
shown in Figure 4.1. There are three plane waves to consider at the boundary : the 
incident wave , the reflected wave and the transmitted wave. The origin of z 
coordinates start on the air-tissue boundary. The boundary condition to apply to the 
electric field at a boundary is that the total tangential electric field on one side of the 
boundary must equal the total tangential electric field on the other side of the 
boundary. The total electric field on transmitted side of the boundary is just Et, hence 
the first boundary condition gives[95]
E i + E r =E,  (Eq- 4.8)
where Ei is the incident wave 
Er is the reflected wave 
Et is the transmitted wave
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Air Boundary Tissue
(z = 0 )
RF
Source
Figure 4.1: Plane waves propagation into tissue
Power conservation states that the total power is constant as the wave is incident on 
the boundary. The average power in the incident, reflected and transmitted plane
E2 E2 E2wave are given by —-  , —-  and —  respectively. Hence, the second boundary 
condition gives[95]
E t E t E f
The wave impedance Zi in air and the wave impedance Z2 in tissue are given b y [95]
z ,= z ja  Z i - Z o J f
where Zo is the impedance of free space. 
ex is the permittivity of free space.
e2 is the relative permittivity of tissue.
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Hy is the permeability of free space.
H2  is the relative permeability of tissue.
Inserting equation 4.8 into equation 4.9 and solving both gives the reflected waves 
and transmitted wave relative to the incident wave.
Hence, the reflected wave relative to the incident wave is given by
The solution relates the amplitudes of the reflected wave to the impedance of the 
waves or the permittivity of the tissue. The ratio Er/Ei is the reflection coefficient 
p  and it is not dependent on the actual power in the plane wave.
The amplitude of decaying electric field of plane wave with the depth z is defined
(Eq. 4.10)
The transmitted wave relative to the incident wave is given by
Et 1Z2 (Eq. 4.11)
b y [94]
E(z) = E0 exp~az (Eq. 4.12)
where a  is the attenuation constant
The power absorbed from a plane wave in a tissue dielectric is defined b y t94]
P(z) = cfE] exp~2az (Eq. 4.13)
where <r is the tissue conductivity
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Tissue is a dielectric that has a very small conductivity and therefore a very small 
loss. The amount of attenuation of a plane wave is determined by the conductivity cr 
of the tissue. Higher tissue conductivity corresponds to a larger attenuation of the 
plane wave. The tissue conductivity cr is defined b y [94]
where co is the angular frequency
8 0  is the permittivity of free space
er is the imaginary part of the complex permittivity sj
The loss tangent, tan(J) is used to describe the amount of loss in the tissue. The same 
tissue that can influence plane waves differently at different frequencies. The loss 
tangent increases as the conductivity increases or the frequency decreases or the 
permittivity decreases. The loss tangent is defined b y [94]
where tan 8 « 1  for waves in low conductivity tissue 
tan 8 » 1  for waves in high conductivity tissue 
eQ is the permittivity of free space
sr is the relative permittivity of tissue 
The attenuation constant a  is defined by
a  -  a)£0er (Eq. 4.14)
tan(£) = -^f = ——— 
er (oe0er
(Eq. 4.15)
(Eq. 4.16)
where c is the speed of light
fdr is the relative permeability 
co is the angular frequency
76
4. Remote Coupling Of Power
sr is the real part of the complex permittivity ej 
£r is the imaginary part of the complex permittivity ej
The attenuation constant value is dependent on the frequency, the relative 
permittivity, the conductivity and the relative permeability of the tissue.
The penetration depth 8 is the distance where the field amplitude is 1/e of the value 
at the surface and is defined b y 1981
(Eq. 4.17)
a
where a  is the attenuation constant of tissue
The phase constants P  is defined b y 1981
(Eq. 4.18)
where co is the angular frequency
Hr is the relative permeability
er is the relative permittivity
The wavelengths in the tissue is defined b y [98]
(Eq. 4.19)
where p  is the phase constant of tissue
The wave velocity v in the tissue is defined by [98]
a>v = — (Eq. 4.20)
P
where P  is the phase constant of tissue
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4.1.2 Tissue Dielectric Properties with Frequency
Tissue is a dielectric material characterised by permittivity and conductivity of the 
tissue. The key factors that determine a wave interaction in tissue are the dielectric 
properties of the tissue. The relative permittivity and conductivity values of tissue are 
highly dependent on the frequency. The characteristic of tissue whose permittivity 
changes with frequency is called a dispersive tissue.[94] It means that if a group of 
frequencies are sent through a tissue, the separate frequencies will be delayed by 
different amounts so that the energy will be dispersed at the other end.
An analysis of dielectric properties of tissues over the range of radio frequencies 
through to microwave frequencies is required for better understanding of the wave’s 
behaviour in tissues. The tissues chosen for the analysis are the skin, fat, muscle and 
blood. The data used in this study for the dielectric properties of tissues are taken 
from C.Gabriel.[92]
The main dielectric properties constants are:
• Wave frequency ( / )
• Tissue real complex permittivity
• Tissue imaginary complex permittivity (e l)
• Tissue conductivity (<r)
• Loss tangent (tan(<5))
• Attenuation constant (or)
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4.1.2.1 Skin
The tissue dielectric properties of skin for the frequency range of 1 MHz to 10 GHz 
are shown in Table 4.1.[921 The real and the imaginary parts of complex permittivity 
of skin gradually decrease with increase in frequency. The conductivity values 
increase with increasing frequency. The attenuation constant increases exponentially 
with frequency. Hence it is recognised that at microwave frequencies, skin conducts 
easily so that it is highly attenuating. Figure 4.2 shows the percentage of power 
transmitted as a function of tissue depth for skin tissue at International Standard 
Medical (ISM) frequencies.
/ cr (S/m) tan(^) ^ (m '1)
1 MHz 990.7595 237.9348 0.013237 0.240154 0.078657
10 MHz 361.6703 354.6898 0.197323 0.980699 1.783913
100 MHz 72.93031 88.30124 0.491242 1.210762 9.557896
1 GHz 40.93626 16.1742 0.899811 0.395107 26.0064
10 GHz 31.29022 14.40529 8.014023 0.460377 263.306
Table 4.1: Tissue dielectric properties of skin.
(a) Skin
100%
13MHz
27MHz
100 MHz
915MHz
2.45GHz
10GHz
0 0.005 0.01 0.015 0.02 0.025 0.03 0.035 0.04 0.045 0.05
Tissue depth (metre)
Figure 4.2: Power transmitted vs. tissue depth in skin tissue.
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4.1.2.2 Fat
The tissue dielectric properties of fat for the frequency range of 1 MHz to 10 GHz 
are shown in Table 4.2.[921 The real and the imaginary parts of complex permittivity 
of fat gradually decrease with increasing frequency. The conductivity values remain 
very low at the lower MHz frequencies and increase gradually in the GHz region. 
The attenuation constant increases exponentially with frequency. This shows that at 
microwaves frequencies, fat conducts easily so that it is highly attenuating. Figure
4.3 shows the percentage of power transmitted as a function of tissue depth for fat 
tissue at ISM frequencies.
/ £l a  (S/m) tan(£) a  (m 1)
1 MHz 50.80411 791.8606 0.044053 15.58654 0.403874
10 MHz 29.58111 94.56821 0.052611 3.196912 1.235533
100 MHz 12.70134 12.29615 0.068407 0.968099 3.306151
1 GHz 11.29422 2.091768 0.11637 0.185207 6.494951
10 GHz 8.801566 3.069381 1.707573 0.348731 106.8514
Table 4.2: Tissue dielectric properties of fat.
(b) Fat
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Figure 4.3: Power transmitted vs. tissue depth in fat tissue.
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4.1.2.3 Muscle
The tissue dielectric properties of muscle for the frequency range of 1 MHz to 10 
GHz are shown in Table 4.3.[92t The value of the real and the imaginary parts of 
complex permittivity of blood reduce with increasing frequency. The conductivity 
values remain approximately constant at the MHz region and rise in the GHz region 
of the spectrum. The attenuation constant increases exponentially with frequency. 
Thus, it is identified that at microwaves frequencies, muscle conducts easily so that it 
is highly attenuating. Figure 4.4 shows the percentage of power transmitted as a 
function of tissue depth for muscle tissue at ISM frequencies.
/ <r (S/m) tan(S) a (m")
1 MHz 1836.314 9035.812 0.502685 4.920625 1.273491
10 MHz 170.726 1108.754 0.616828 6.494346 4.57042
100 MHz 65.97206 127.1904 0.707592 1.927943 13.03052
1 GHz 54.81103 17.583 0.978186 0.320793 24.58134
10 GHz 42.76354 19.10054 10.62611 0.446655 299.0463
Table 4.3: Tissue dielectric properties of muscle
Figure 4.4: Power transmitted vs. tissue depth in muscle tissue
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4.1.2.4 Blood
The tissue dielectric properties of blood for the frequency range of 1 MHz to 10 GHz 
are shown in Table 4.4.1921 The real and the imaginary parts of complex permittivity 
of blood gradually decrease with increasing in frequency. The conductivity values 
remain approximately constant at the lower frequencies and increases in the higher 
frequencies region. The conductivity constants are apparently proportional to 
frequency but the frequency dependence of the complex permittivity often dominates. 
The attenuation constant increases exponentially with frequency. Consequently, at 
the microwave region, blood conducts easily so that it is highly attenuating. Figure
4.4 shows the percentage of power transmitted vs. tissue depth for muscle tissue at 
ISM frequencies.
/ cr (S/m) tan(£) a  (m' )
1 MHz 3026.738 14777.52 0.82211 4.882325 1.627324
10 MHz 280.0937 1971.54 1.096817 7.038861 6.130559
100 MHz 76.82191 221.6598 1.233149 2.885372 18.61488
1 GHz 61.06537 28.45584 1.58307 0.46599 37.21117
10 GHz 45.10917 23.60412 13.13156 0.523267 356.9846
Table 4.4: Tissue dielectric properties of blood
(d) Blood
100%
90%
80%
13MHz
27MHz
100MHz
915MHz
2.45GHz
10GHz
0 0.005 0.01 0.015 0.02 0.025 0.03 0.035 0.04 0.045 0.05
Depth into tissue (metre)
Figure 4.5: Power transmitted vs. tissue depth in blood tissue
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4.1.3 Summary of the Frequency Analysis
The analysis of various tissue dielectric properties shows that blood is the most 
attenuating tissue in comparison with the other tissues. This is followed by muscle, 
skin and lastly fat as the least attenuating tissue. The tissue penetration depth 
achieved at low frequencies is much higher than at microwaves frequencies. This is 
because at lower frequency, there is less attenuation in these tissues and therefore 
more power could be transmitted through the tissues. At microwave frequencies, the 
waves could only be penetrating up to 1-2 cm depth in which most of the power is 
being absorbed in the first centimetre of the tissues.
4.2 Wave Propagation Model
A wave propagation model named WAVEP was developed to predict the penetration 
depth of a plane wave propagating through a human body. The human body is 
represented by a simple one dimensional, multi-layer structure incorporating the skin, 
fat, muscle and tumour. Each layer has its own tissue dielectric properties, namely 
relative permittivity ex and attenuation constant or,. The physical dimensions of skin,
fat, muscle and tumour were taken as representative of a tumour located in the body. 
The tumour was assumed to contain blood vasculatures. It was assumed that the 
plane wave was perpendicular incident to the skin surface to simplify the complex 
reflection of waves in the tissues.
Figure 4.6 shows five boundaries with a single wave incident on the first boundary. 
At the first boundary, the wave is partially reflected and partially transmitted and the 
same thing happens at the second boundary. A part of the wave is reflected back to 
the first boundary which is then partially reflected and partially transmitted. The 
result is that the total field at the first boundary consists of multiple individual waves. 
The wave is partially reflected and partially transmitted at each boundary until it 
reaches the final end of the tissues.
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Air Skin Muscle MuscleFat Tumour
Plane
wave
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z=o
Figure 4.6: Simplified model of RF waves propagation into human body
The total electric field amplitude in each boundary consists of the sum of the 
individual components. The following total electric field equations were derived 
from equation 4.8 and equation 4.12.
In the first boundary Bi, the total field at z = 0 is given by
Eti = Ei0 +Er0  (Eq. 4.21)
In the second boundary B2, the total field at ziis given by
Etl = En exp_aiZl + Erl exp-^  (Eq. 4.22)
In the third boundary B3, the total field at Z2 is given by
Ea = Et2 exp-** + Erl exp"*2*’ (Eq. 4.23)
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In the fourth boundary B4, the total field at z3 is given by 
EtA = Et3 exp ""32j + Er3 exp" * 523 
In the fifth boundary B5, the total field at Z4 is given by 
Et 5 = Et 4 exp" " 424 + Er4 exp' " 424 
The total transmitted field at the end of the tissues or Z5 is given by 
Et =Et 5 exp' " 323
(Eq. 4.24)
(Eq. 4.25)
(Eq. 4.26)
The solution to the problem requires that the values of Eu, Eg, Eg, Et4, Ets and E^, 
Eri, Er2, Et3, Et4 relative to Eio to be found. This requires a total of ten boundary 
equations to be solved. The following boundary equations were derived from 
equation 4.10 and equation 4.11.
For boundary condition 1,
Er 0 _ ^  ~~
E I0  V « b + V ^
For boundary condition 2,
E t\ _  ^yf^o
^io y[&o + yf& i
For boundary condition 3,
Er l _ 2^  1
Ei 0 <y[^i + y[^ 2 j ^yfzo+yjzi j
For boundary condition 4,
E t2 _ r  ] r  2 7 ^  1
E * ^ y f ^ i  + y[^ 2 j . y f c  + y f c  j
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For boundary condition 5,
Er l _ yfp2 [^^ 3 r  ^  } ]
E, o j <yf^i +  y[^ 2 j o f t  +  A  J
For boundary condition 6 ,
_ r  ^  ] r  ] r  2 ^  ^
E< o + yf^ i j
For boundary condition 7,
E r l _ y[^ 3 y[^ 4 ] 1 r  2 ^  i
Ei0 ^yf^3+ yf^4 j ^y[£2 + yj£3 j ^yf^i +  yf^ 2 ^ ^yj^o ^~y[^i >
For boundary condition 8 ,
f  ^  ] r  2 ^  ] ] r  2 ^  i
<y[^3+ yf 4^ ^ + y f&3 j ^ y f ^ i  + yf 2^ j ^yf^o ^ y f ^ i j
For boundary condition 9,
E r4 _ 2y f e  ) r  2 j r 2 i 2^  ] r  2 ^  )
* * 0 <yf^4 + yf 5^ ^ <yf^3+ yf 4^ , ^ y f z ^  + yf&i + y[^ 2 > ^ y f e  + y f e  j
For boundary condition 10,
2&  1 2&  ] r  2 ^  ] 2 ^  1 r  2 ^  i
^ yfsi + y js 3 , ^yl&l + y f&2 j
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The boundary conditions and the total electric field equations at the boundaries 
require the relative permittivity and attenuation constant of the tissues to be known. 
The relative permittivity and the attenuation constant of skin, fat, blood and muscle 
for the model are obtained from C.Gabriel. 1921 By using 100% incident power as the 
source, the wave propagation through the tissues was modelled. The result of this 
model indicated what percentage of incident wave power reached the target tumour 
after passing through the upper layers of the skin, fat and muscle tissues. The 
physical parameters in Table 4.5 are taken as being representative of tissues in the 
body.
Tissue Structure Thickness
Skin 2.5mm
Fat 2.5mm
Muscle (Top) 1 cm
Blood ( Tumour) 4mm
Muscle (Bottom) 3cm
Table 4.5: Physical dimension of the tissues in the body
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4.2.1 Wave Propagation Model Results
Figure 4.7 below shows the results of the wave propagation in tissues for a range of 
ISM frequencies using the physical properties of the human body in Table 4.5.
—  13 MHz
—  27MHz
—  100 MHz 
 915MHz
2.45GHz 
— -10GHz
* 40%
*£
~ 30%5•a
© 20%
Skin Fat Muscle Blood
60%
Muscle
0.005 0.015 0.02 0.025 0.03 0.035
Depth into tissues (metre)
0.045
Figure 4.7: Power transmitted as a function of tissue depth from air into tissues
The wave propagation model shows that at least half of the incident waves power at 
all frequencies is being reflected out of the surface skin. This is due to the impedance 
mismatch between the air and the layer of the skin. Although the waves have less 
attenuation in the tissues at 13 MHz and 27 MHz, most of the incident waves at these 
frequencies are reflected out of the body. This means less energy absorbed in the 
tissues from a very low initial coupling into tissues. At the microwave frequencies 
2.45GHz and 10GHz, the amount of power reflected at the skin boundary are lower. 
Hence, there are more power coupled into the tissues but the waves are highly 
attenuated inside the tissues. The power level decreases rapidly with increasing tissue 
depth as most of the power is absorbed by the tissues. This gives a very low 
penetration depth of 1-2 cm into tissues. If the embedded device is assumed to be 
located close to the blood vessel, the best frequency for energy transfer would be the
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100 MHz. The 100 MHz frequency provides 20% incident wave power at 1.5 cm 
depth with lower absorption in the skin and fat layers compared to 915MHz.
In order to reduce the incident wave reflected out of the body, the incident 
waveguide may be filled with low loss dielectrics. An example is a water-filled 
waveguide used in direct contact with skin. Water has a relative permittivity value of 
approximately 80. The impedance of water (42 Ohms) is closely matched to the skin 
impedance range (10-70 Ohms) in comparison to the impedance of free space (377 
Ohms). Figure 4.8 below shows the results of the wave propagation in tissues for 
various ISM frequencies using a water-filled waveguide.
Skin Fat Muscle Blood Muscle
100%
90%
80%
—  13 MHz 
— 27 MHz 
— 100 MHz 
— 915MHz
2.45GHz40%
—  10GHz
30%
20%
10%
0%
0.005 0.01 0.015 0.02 0.025 0.03 0.035 0.04 0.045 0.05
Depth into tissues (metre)
Figure 4.8: Power transmitted as a function of tissue depth from water into tissues
The wave propagation model shows a significant increase in the initial coupling 
power and very little power is being reflected out of the body. This is due to the 
impedance matching between the water and the layer of the skin. At lower 
frequencies of 13MHz and 27MHz, the waves can penetrate deeper into the tissues 
with less energy absorbed in the tissues. This gives higher coupling power at greater 
tissue depth compared to other frequencies. At microwaves frequencies, the range of 
penetration depths that can be achieved is still only 1cm to 3cm.
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4.3 Remote Coupling Methods
Two methods to distinguish and categorise remote coupling are inductive coupling 
and radiative coupling. Both methods are based on two different operating principles. 
Inductive coupling is based upon close proximity magnetic field and radiative 
coupling is based upon electromagnetic waves propagation.
4.3.1 Radiative Coupling
RF systems operating in the ultra high frequency (UHF) and microwaves range make 
use of conventional electromagnetic wave propagation for energy transfer. Devices 
placed within the field are immersed in this propagating wave and receive the energy 
as it passes. The amount of energy available at any particular point is related to the 
distance from the transmitter and may be expressed as 1/d2 where d is the distance 
from the transmitter. On the contrary of a induction system, the field strength of the 
transmitted energy drops at 1/d3 depending on the orientation of the device to the 
transmitter.[98] In practice, the operating range is dependent on the radiated power of 
the transmitter, the operating frequency and the size of the receiver antenna.
The power density is not influenced by frequency but by the effective radiated power, 
however, the received coupled power is dependent on antenna size. The amount of 
energy collected is a function of the length of the receiving antenna, which in terms 
is related to the wavelength.
For resonant effect in the receiver, the minimum length required for a dipole antenna 
is half a wavelength[99] Table 4.6 shows the minimum length required for dipole 
antennas at UHF and microwave frequencies.
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Frequency Wavelength lA Wavelength
433MHz 70cm 35cm
915MHz 32cm 16cm
1GHz 30cm 15cm
2.45GHz 1 2 cm 6 cm
5 GHz 6 cm 3cm
10GHz 3cm 1.5cm
Table 4.6: Minimum dipole length at UHF and microwaves frequency
In the UHF, the minimum length for dipole antennas range from 16cm to 35 cm 
which makes it impossible for practical use. Design of dipoles to operate at lower 
frequencies (<5 GHz) usually leads to impractical dimensions for the antenna. In the 
microwave region, the reasonable wavelength needed for practical application falls in 
between 5GHz and 10GHz. At these wavelengths, the waves are highly attenuating 
in tissues and have very low penetration depth into tissues. Over ninety percent of the 
power could be lost or absorbed in the first 2 cm of the tissue, as predicted in the 
wave propagation model. The receiving antenna may be made physically smaller, but 
there are tradeoffs to reducing the antenna size, such as the reduction in the critical 
tuning and coupling power. Hence, this suggests that radiative coupling method is 
not suitable for energy transfer into tissues for the embedded device application.
4.3.2 Inductive Coupling
The basic operating principle of inductive coupling is energy transfer by the use of 
the magnetic field component. A small antenna of the transmitter consists of 
induction coils that generate a magnetic field which induces a voltage in the coils in 
the receiver and supplies the device with energy. The magnetic flux linkage and 
energy exchange occurs between the two resonant loop coils having the small but 
finite coefficient of coupling between them as shown in Figure 4.9. The inductive 
coupling method is commonly operated in the range 10-30MHz. At frequencies less 
than 10MHz, much higher coil currents are required, while operating at frequencies 
greater than 30MHz may results in increased heating of superficial tissues. 11001
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Figure 4.9: Energy transfer between two induction coils
The benefit of using a low frequency is that the energy transfer is primarily magnetic. 
Unlike UHF and microwave systems, the magnetic field at 10-30MHz is not 
absorbed by water or human tissues, which allows operation through human body. 
The magnetic field will penetrate human tissues with little or no loss in field strength. 
This is due to the fact that the relative permeability of human tissues in the body is 
equal to unity. Hence, it is suggested that a RF receiver device could be remotely 
powered while embedded inside human body.
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4.3.2.1 Magnetic Field in Transmitter Coil
Ampere’s law states that current flowing in a conductor produces a magnetic field 
around the conductor. The magnetic field produced by a transmitter circular loop coil 
is given b y tl01]
H = E ^ ~  (Eq.4.27)
where H is the magnetic field strength
fi0 is the permeability of free space
N is the number of turns of coils in loop 
I is the current flowing through loop 
A is the radius of loop 
r is the distance from the centre of the loop
The optimum transmitter coil diameter is given b y tl01J
A = j2 r  (Eq. 4.28)
where A is the radius of loop
r is the required coupling distance
The equation 4.6 shows that the magnetic field strength decays with the 1/r3, which 
means that the required transmission power decreases with 1/r6. The 1/r3 relationship 
has its advantageous, as the system will have a high magnetic field level in its 
immediate proximity but a very low level in the far field. Hence the magnetic field 
generated will not cause interference with other electronic devices in a distant space. 
The field has maximum amplitude in the plane of the loop and directly proportional 
to both the current and the number of turns, N. The operating region of inductive 
coupling systems is in the near field of the transmitter coil, which results in 
achievable operating distances of approximately the radius of the transmitter coil.
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The inductance of a single turn circular coil is given b y 11011
L = 0.01257(^4) 2.303 log r \6A '10 - 2 (Eq. 4.29)
where A is the radius of loop 
d is the diameter of wire
The inductance of N-tum single layer circular loop coil is given b y 11011
L = — (AN)  ^  4.30)
22.9^ + 25.4/ ’
where A is the radius of loop
N is the number of turns of coil 
I is the length of the loop
The inductance of an N-tum multilayer circular loop coil is given b y 11011
L = ™ ± M L  (Eq. 4.31)
6a + 9h + 106
where A is the radius of loop
N is the number of turns of coil 
b is the winding thickness 
h is die winding height
4.3.2.2 Induced Voltage in Receiver Coil
Faraday’s law states that a time-varying magnetic field through a surface bounded by 
a closed path induces a voltage around the loop. The induced voltage in the loop 
causes a flow of current on die loop.
The induced voltage in a receiver tuned loop coil is given by 11011
VQ = 27tfNSQH cos 0  (Eq. 4.32)
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where / i s  the frequency of the transmitter
N  is the number of turns of coils in the loop 
S is the area of the loop 
Q is the quality factor of circuit 
B is the magnetic field strength available at the loop 
0 is the angle of rotation
The inductive coupling system is relatively immune to the orientation of the device 
with respect to the transmitter. When a transmitter coil and a receiver coil are placed 
in the same plane, the coupling between them will be a maximum. A rotation away 
from optimum alignment will therefore result in a reduction in the coupling by the 
cosine of angle of rotation. Table 4.7 shows the reduction in coupled energy with 
rotation of coil.
Angle Coupling
0 ° 1 0 0  %
15° 96%
30° 8 6 %
45° 70%
60° 50%
75° 25%
oO00 17%
oOO00 3%
90° 0 %
Table 4.7: Angle of rotation of coil with coupled energy.
As the angle turns towards 90°, there will still be coupling, even though at reduced 
range. In practical systems, the effect of device orientation with respect to the 
transmitter coil is not very critical as the transmitter coil can be placed in the same 
plane as the device. 11021 The inherent curvature of the magnetic flux lines also assists 
coupling to the device under suboptimum device orientations.
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4.3.2.3 Tuned Resonant Circuit
The receiver’s ability to draw energy efficiently from the transmitter is based on the 
electrical resonance effect. To enable maximum transfer of power, the receiver 
should have a tuned resonant circuit. An example of a parallel resonant circuit is 
shown in Figure 4.10.
I
Figure 4.10: Parallel resonant circuit.
The inductor L and capacitor C are connected in parallel with the series resistance R 
of the coil. An alternating voltage V is applied across both L and C, and the current 
through the inductor is given b y [103]
h = B, „  (Eq4.33)
R +{j.nfL)
The current through the capacitor is given by [103]
Ic =2nfCV  (Eq. 4.34)
When the currents ligand Ic are such that the resultant current I is in phase with the 
voltage, the circuit is said to be in parallel resonance. An example of a phase diagram 
of the resonance circuit is shown in Figure 4.11.
96
4. Remote Coupling Of Power
Ic
Figure 4.11: Phase diagram
When in resonance,
Ic = OA = ILsin0 (Eq 4.35)
. . ,  reactance of coil 2k  fLwhere sin(9 = ---------------------- =
lmpedance of coil J r 2 + (2k fL)1
Substituting equation 4.33 and equation 4.34 to equation 4.35 gives
/  = -------, }  - (Eq.4.36)
2kL. r L '  L - Ri t
C /
If the R is small compared with 2k  f L , then equation 4.36 becomes[103]
This shows that the receiver circuit must be tuned to the operating frequency to 
maximize power efficiency.
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The quality factor of the coupling inductor defines how well the resonating circuit 
absorbs power over its relatively narrow resonance band The phase diagram in 
Figure 4.11 shows that when resonance occurs in parallel circuits, the current 
circulating in L and C will be many times greater than the resulting current The 
quality factor of the circuit is given by
Figure 4.12 illustrates the effect of resistance on the quality factor of a parallel 
resonant circuit. At resonance, the induced RF voltage produced across the tuned 
circuit and delivered to the device will be few times greater than for frequencies 
outside of the resonant bandwidth. The resultant current in a resonant parallel circuit 
is in phase with the supply voltage, with the impedance given by
Therefore, a parallel resonant circuit is equivalent to a resistor of L/CR and is termed 
the dynamic impedance of the circuit.
(Eq. 4.38)
(Eq. 4.39)
M
High Q
Current
Medium Q
LowQ
Frequency
Figure 4.12: Effect of quality factor on a parallel tuned circuit
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The energy in a resonant circuit which is partly electromagnetic and partly 
electrostatic, is given by
E = ^ L I 2 + |C K 2 (Eq. 4.40)
At the moment when the capacitor is completely discharged, the energy is stored 
entirely in the inductor; while a quarter of a cycle later, when the current is zero, the 
energy is stored entirely in the capacitor. The cycle continues to change from one 
form to the other during the continuance of the oscillation.
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4.4 Design and Evaluation of RF System
4.4.1 Transmitter and Receiver Design
The RF system consists of a RF transmitter operating at 13.56MHz and a RF receiver 
as shown in Figure 4.13. The advantageous of using a 13.56MHz RF system are 
listed as follows:
• The frequency band 13.56MHz is an ISM frequency.
• Technology widely available in the RFID security system.
• No user licenses or RF-shielded rooms required (ISM band).
• Defined and localised coupling area.
• Immunity to electrical interference.
• Attenuation effects are relatively small as magnetic field penetrates
dense tissues.
• Minimal reflection effects from the human body.
• Cost effective antenna coil manufacturing.
RF Transmitter
13.56MHz
Generator
Magnetic Field
LED Device
RF Receiver
r
Figure 4.13: Schematic diagram of a RF system
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The design of a RF system based on the 13.56MHz generator and the LED device 
uses equivalent electrical circuits as shown in Figure 4.14.
Cf
Ct
Figure 4.14: Equivalent circuits of the RF transmitter and the RF receiver
where Rl, R2 is the series resistance of the coil
LI is the transmitter circular loop coil inductance
L2 is the receiver coil inductance
Cf is the device parallel capacitance
Ct is the device tuning capacitance
D is the device diode
LED is the light source
From the equation 4.27 and equation 4.32, the parameters to optimise the maximum 
induced voltage in the device are:
a) Current flowing through L1 coil
b) Angle of LI magnetic flux to L2 magnetic flux
c) Distance between LI and L2 coils
d) Radius and number of turns of LI coil
e) Surface area and number of turns of L2 coil
f) Quality factor of parallel resonant circuit
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The 13.56MHz RF generator used in the tests was an Advanced Energy RFX-600 as 
shown in Figure 4.14(a). The RFX-600 is a two-stage power generator using a 
modular power amplifier and a switch mode dc power supply for main power and 
control. It is capable of 600Watts maximum output power into a 50 Ohms load.
l iL  if PKf?RFX-600 I  R E FLEC T ED  PO W ER I
m m m
DISPLAYOUTPU1 I  PO W ER LIMIT I  PO W ER LEVEL
r f  R r
O N
L E F T  R I 8 H T  
0 I 8 P L  AT D I 8 P L  AT
rn in  ec IIM
5 R EG U LA TIO N REMOTES
Figure 4.14(a): Advanced Energy RFX-600 RF generator
The transmitter coils used for LI was a 15AWG copper enamelled wire as shown in 
Figure 4.15. Three different loop sizes and N-tum of coils were used in the tests.
Wire diameter 1.5mm
Resistance 3.18 Ohms / 1000 feet
Insulation Coating Polyurethane
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Figure 4.15: 15AWG copper enamelled wire
The two inductors of different sizes for L2 used in the tests were 10 pH ferrite core 
rod inductor and 10pH surface mount inductor.
a) lOpH ferrite core rod inductor (L2r0d) as shown in Figure 4.16.
Diameter 9.5mm
Length 30.5mm
Resistance lO.OmQ
b) lOpH surface mount inductor (L2sm) as shown in Figure 4.17.
Diameter 9.7mm
Length 5mm
Resistance 47mQ
Figure 4.16: Ferrite core rod inductor.
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Figure 4.17: Surface mount inductor.
A sub-miniature HLMP-Q150 645nm LED was used in the receiver circuit as shown 
in Figure 4.18.
Length x Width x Height 2.15mm x 2.2mm x 2.15mm
Peak wavelength 645nm
Forward voltage 1.6 V
Typical forward current 1 mA
Maximum forward current 20mA
Luminous intensity 1.8mcd @ 1mA
Figure 4.18: HLMP-Q150 LED.
104
4. Remote Coupling Of Power
4.4.2 Induced Voltage against Distance
Figure 4.19 below shows the equivalent electrical circuit of Test 1 setup.
R1 R2
W V A A /V
o
a
13.56MHz Vac
12
where LI = 0.48nH R1 = 3.84 m£2 L2rod = lO^H R2rod = 10m£2
L28m= 10^H R2gm = 47mD
Figure 4.19: Equivalent electrical circuit of Test 1
To examine the effect of current flowing through the L I coils, two values of 
transmitter powers 5W and 10 W were used. A 12cm diameter single turn circular 
coil was used for L I. Two different size of 10pH inductors were used for L2 namely 
rod inductor (L2rod) and surface mount inductor (L2sm). The inductor L2 positions 
were varied from the centre of the loop of LI up to 10cm distance in the z-axis as 
shown in Figure 4.20.
x
y
z
Figure 4.20: Inductor L2 positions (r) in the z-axis
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The magnetic field strength produced with the 5W power was 
H = 0.263mA/m @ 1 ^  = 0.146A
The magnetic field strength produced with the 10W power was
H = 0.389mA/m @ Irms = 0.216A
The induced voltage of L2rod and L2sm were measured using an Agilent Signal 
Oscilloscope S4622D. Figure 4.21 and Figure 4.22 show the maximum induced 
voltage VL2 across L2rod and L2sm as a function of distance.
The first test results showed that when the transmitted power were doubled, more 
current flows through LI and therefore induced voltages in L2ro<i and L2smare higher. 
The induced voltage decays exponentially due to decrease in the magnetic field 
strength with distance. L2rod has a higher induced voltage compared to L2sm for the 
same amount of transmitted power. This is because of the greater L2rod surface area 
and length.
 5W
10WO il
x
Distance (cm)
Figure 4.21: Maximum induced voltage in the rod inductor
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----- !
fN 5W
10Won
Distance (cm)
Figure 4.22: Maximum induced voltage in the surface mount inductor
To determine the effect of the angle of LI magnetic flux to L2 magnetic flux, the 
orientation of L2 to LI was adjusted and placed so that the induced voltage of L2 
was at the minimum and maximum. Figure 4.23 and Figure 4.24 show the maximum 
and minimum induced voltage VL2 across L2rod and L2sm as a function of distance at 
10W transmitted power.
g  40
Maximum
 Minimum
Distance (cm)
Figure 4.23: Induced voltage in the rod inductor at 10W power.
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 Maximum
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Figure 4.24: Induced voltage in the surface mount inductor at 10W power
The inductor displacement test results showed a large reduction in the induced 
voltage for L2 when the position of L2 was tangential to the position of LI. The 
maximum induced voltage is only achieved when L2 was placed parallel to the LI 
magnetic flux plane.
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4.4.3 Generated Current against Distance
Figure 4.25 below shows the equivalent electrical circuit of Test 2 setup.
Ammeter
LI
L2rod=10nH R2rod=10mQwhere Ll=0.48jiH R1 = 3 .84 m£l
L2sm=10^xH R2sm = 47mO
Figure 4.25: Equivalent electrical circuit of Test 2
To determine the minimum power requirement of the transmitter to generate 1mA of 
current into the LED, the range of 1-50W transmitter powers were used. The current 
flowing through the LED was measured using an ammeter. Figure 4.26 and Figure 
4.27 show the LED current for L2rod and L2sm as a function of transmitter power at 
the distance of l-3cm.
1 cm
2 cm
3 cm
20 30
Power (W)
Figure 4.26: LED current vs. transmitter power for L2rod
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Figure 4.27: LED current vs. transmitter power for L2sm
The second test results showed that the power required for L2rod to provide 1mA 
current into LED at 1cm distance is 16W. At 2cm distance, the power needed 
increases to 27W. The maximum distance allowable for LED operation is 4cm at 
50W transmitted power. For the L2sm, the highest LED current attainable from 1cm 
distance is 0.4mA at 50W transmitter power. This is because of the higher resistance 
and less induced voltage across L2sm.
4.4.4 Induced Voltage in RLC against Distance
A parallel resonant circuit (RLC) with a resonant capacitor Cf, a tuning capacitor Ct 
and a diode were added to the receiver circuit. Figure 4.28 shows the equivalent 
electrical circuit of Test 3 setup.
The resonant circuit was connected to an oscilloscope and the tuning capacitor was 
tuned while observing the signal amplitude on the oscilloscope. The tuning was 
stopped at the maximum voltage. Figure 4.29 show the maximum induced voltage 
across Q as a function of distance at 10W transmitted power.
110
4. Remote Coupling O f Power
R1
AA/V
where LI = 0.48^H
LI
N— W v
A
V
0
0
, 
1
R1 = 3 .84 mQ L2rod=10|iH R2rod =: lO.OmlQ
L2sm=10^H R2sm = 47mQ
Cf = 5.2 -  30pF 
Q =  1.5pF-5pF
Figure 4.28: Equivalent electrical circuit of Test 3
 L2(rod)
 L2(sm)
0 2 4 6 8 10
Distance (cm)
Figure 4.29: Induced voltages for L2rod and L2sm at 10W power
The third test results showed that the induced voltages for L2rod and L2sm decay with 
distance. Again, the voltage induced in the L2rod is higher than the L2sm because the 
L2roa has a larger surface area and length.
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4.4.5 Generated Current in RLC against Distance
Figure 4.30 below shows the equivalent electrical circuit of Test 4 setup.
Ammeter
13.56MHz Vac
LED
- r - C t
where Ll=0.48pH = 3.84 mO L2rod = lOpH R2rod =: 10.0m£2
Clsm = lOfiH R2 sn, = 47mQ
Cf= 5.2 -  30pF 
1.5pF-5pF
Figure 4.30: Equivalent electrical circuit of Test 4
To compare the power requirement of the transmitter to generate 1mA current in the 
LED of a resonant circuit (RLC) and a non-resonant circuit (non-RLC), the range of 
1-50W transmitter powers were used. The current flowing through the LED was 
measured using an ammeter. Figure 4.31 and Figure 4.32 show the LED current at 
resonance and non-resonance for L2rod and L2sm as a function of power.
7
6
5
 lcm (RLC)
2cm(RLC)
 lcm(non RLC)
 2cm(non RLC)
4
3
2
1
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Power (W)
Figure 4.31: LED current for L2rod in the resonant and non-resonant circuits.
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Figure 4.32: LED current for L2sm in the resonant and non-resonant circuits.
The fourth test results showed that less power is required to provide 1mA current 
into LED with resonant circuit compared to non-resonant circuit at a fixed distance. 
This is because the quality factor of the parallel resonant circuit increases the current 
available in the capacitor.
4.4.6 Effects of Transmitter on Induced Voltage
The same setup of Test 3 was used in this Test 5 with the use of three different LI 
configurations. The three LI configurations that were used to investigate the effects 
of the transmitter on the L2 induced voltage were
a) 12cm diameter single turn circular coil (LI 12 = 0.48gH)
b) 6cm diameter single turn circular coil (Ll6 = 0.22pH)
c) 12 cm diameter 3-tum circular coil (LI i2a = 2.18pH)
Figure 4.33 and Figure 4.34 show the maximum induced voltage in L2rod and L2sm 
for three LI configurations.
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Figure 4.33: Induced voltage in L2rod at 10W power.
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Figure 4.34: Induced voltage in L2sm at 10W power.
The fifth test results showed that LI 12 was best coupled with L2rod and L2sm at 
distance up to 3cm. Beyond 3cm distance, the use of LI i2a generates a higher 
induced voltage than LI i2 and L l6. The LI j2a induced the highest voltage over the 
entire 10cm distance in the L2sm .This showed that the radius of LI determined the 
optimum operating distance of L2. The increase in number of turns of LI coil also 
helped to increase the induced voltage in L2.
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Next, the identical setup of the Test 5 was used in the transmitter y-axis test. In this 
test, the inductor L2 positions were varied inside the LI loop from the centre of the 
loop (Ocm) to the outer circle of the loop in the y-axis as shown in Figure 4.35.
x
y
Figure 4.35: Inductor L2 positions (r) in the y-axis.
Figure 4.36 and Figure 4.37 show the maximum induced voltage in L2rod and L2sm 
for three LI configurations.
140
120
100
 Ll(12)
LI (6) 
Ll(12a)
Loop Distance (cm)
Figure 4.36: Induced voltage in L2r0d at 10W power.
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Figure 4.37: Induced voltage in L2sm at 10W power.
The curves of Figure 4.30 and Figure 4.31 showed that L2 induced voltage increases 
when the L2 was positioned nearest to the outer loop of LI. This means that at the 
centre of the loop, the magnetic field is the weakest. The Lie induced the highest 
voltage throughout the loop distance as the magnetic flux was more concentrated due 
to area of Lie being smaller. LI i2 and L l6 had a lower induced voltage in the centre 
of the loop and the outer loop which suggest that increasing the loop size could cause 
the magnetic field in the centre of the loop to drop to zero. Hence, this test showed 
that the inductor position in the transmitter y-axis produce a higher voltage than the 
inductor position in the transmitter z-axis. This suggests that transmitter loop coil 
could be wrapped around the human hand or the human leg to couple the magnetic 
field energy into tissue for embedded photodynamic therapy.
4.4.7 Effects of Bacon Tissue on Induced Voltage
The next test was to examine the effect of tissue on the coupled magnetic field and 
the induced voltage. The transmitting coil LI and the receiver coil L2a were 
positioned 3cm apart. The induced voltage across the air was recorded as the air 
reference level. Next, a bacon tissue of 2cm thickness was placed in between LI and
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L2a. The induced voltage across the bacon was recorded. It was observed that the 
induced voltages across the air and across the bacon have the same voltages. This 
showed that the bacon tissue has no effect on the induced voltage and therefore, does 
not absorb the magnetic field energy. These finding suggest that the magnetic field 
energy is able penetrate deeply into tissues without the attenuation losses.
4.4.8 Summary of the RF System
The techniques to generate maximum magnetic field strength at the transmitter coil 
are:
• The optimum coil diameter of the transmitter coil should be two times the 
coupling distance between transmitter and receiver for maximum magnetic 
flux density.
• The wire used in transmitter coil should be low resistance wire to allow 
maximum current flowing through the coil.
• The increase in number of turns of transmitter coil increases the magnetic 
field coupled into the receiver.
• The centre of the transmitter coil should be placed at the receiver and parallel 
to the receiver for efficient coupling.
The methods to induce maximum voltage in the receiver and to reduce the dimension 
of the receiver are:
• When higher operating frequency is used for the transmission, the size of the 
receiver coil could be reduced considerably.
• The length and the diameter of the receiver coil should be chosen to the 
smallest dimension required as possible.
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• The transmitter power can be controlled to compensate for the low induced 
voltage in a smallest receiver coil size.
• The capacitor and inductor values must be tuned to the operating frequency 
for resonance in the circuit.
• The quality factor of resonant circuit increases the current available to the 
LED very much.
• The LED and the capacitor could be added into an integrated chip that has a 
very small silicon area.
The RF investigational tests carried out clearly suggests that, the use of inductive 
coupling principle is an efficient method to couple energy into the human body to 
power the embedded LED device without the attenuation losses in tissues..
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4.5 Design and Evaluation of Microwave System
The microwave system consists of a microwave generator, a network analyser and an 
input-output test set. The microwave generator is a Wiltron 68137A Sweep 
Generator with frequency range of 2 GHz to 20 GHz and maximum output power of 
+ 13dBm. The network analyser is a Wiltron 360B Vector Network Analyser. The 
Wiltron equipments used are shown in Figure 4.38 and the equivalent circuit diagram 
is shown in Figure 4.39.
Figure 4.38 Wiltron microwave equipments.
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Input/Output Set
Microwave
Generator
Coaxial
cable
Coaxial
cable
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Waveguide MUD D /V Q Waveguide
4 cm
Figure 4.39 Equivalent circuit diagram of a microwave system.
Three different types of animal tissues that were used in the analyses are
a) Chicken Skin
b) Bacon
c) Ham
The wavelengths that were used for the analyses range from 2.55GHz to 3GHz. The 
source power of the microwave generator was set at 5dBm or 3.16mW. Both of the 
waveguides were cylindrical tubes with 3cm monopoles to match a cut-off frequency 
of 2.5GHz. The waveguides were separated at 4cm distance apart. Then, the animal 
tissues were placed in between the waveguides. The attenuation losses in the tissues 
were measured using the Wiltron network analyser.
4.5.1 Attenuation against Frequency for Chicken Skin Tissue
In this analysis, a 1mm thickness fresh chicken skin was used. Firstly, the 
measurements of the power across the air were taken as the reference level. Next, a 
slice of chicken skin was placed in between the waveguides and the microwave 
power across the skin was measured. Figure 4.40 shows the attenuation in the 
chicken skin as a function of frequency.
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Figure 4.40: Attenuation in the chicken skin as a function of frequency.
The results showed that the microwave power diminish through the skin and vary 
with frequencies. At 2.6GHz, there was a loss of -3.727dBm or -57.6% reduction of 
power. The impedance mismatch between the air and skin causes most of the 
incident microwave power being reflected at the skin surface. The results were 
comparable with the RF propagation model which predicted -57% loss of power in a 
1mm human skin. The reflection loss at the skin-air surface was assumed to be 45% 
of the incident microwave power.
The microwave power available at a thickness x in the tissue is given by 1951
P(x) = (PQ - P r)exp(-2crjc) (Eq. 4.41)
where P(x) is the power at thickness jc
P0 is the power of the incident microwave at thickness x = 0 
Pr is the power reflected 
a  is the attenuation coefficient
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An estimate for the attenuation coefficient of a chicken skin at 2.6GHz frequency 
was calculated by using equation 4.41, to be
4.5.2 Attenuation against Frequency for Bacon Tissue
In this investigation, four slices of fresh bacon were used with each slice has an 
average thickness of 4mm. The measurements of power across the air were taken as 
reference level. Next, a slice of bacon was placed in between the waveguides and 
power measurements were taken. Subsequently, another slice of bacon was added 
and the power measurements were repeated. This process continued until four slices 
of bacon were used up. Figure 4.41 shows the attenuation in the bacon as a function 
of frequency.
P(0.1) = 0.424 = (1 -  0.45) exp(-2 *0.1 * a)  
a  =1,30cm 1 ±0.21
(Eq. 4.42)
30
20
♦ ■ Air
- X-- 8mm (2 Slices) 
—■— 12mm (3 Slices) 
—•—  16mra (4 Slices)
4mm (1 Slice)
-50 -
-60
Frequency ( Ghz)
Figure 4.41 Attenuation in the bacon as a function of frequency.
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The results of Figure 4.42 showed that the power loss increases exponentially with 
the increasing bacon thickness. At 2.6GHz, the power loss in the 4mm bacon was 
-16.335dBm. The power loss increased to -23.918dBm in the 8mm bacon. The power 
reflected at the bacon-air surface was calculated to be 87.3% of the incident 
microwave power using linear regression line analysis. The attenuation coefficient of 
a bacon at 2.6GHz was calculated by using equation 4.41, to be
/ >(0.4) = 0.0233 = (1 -  0.873) exp(-2 * 0.4 * a)  (Eq. 4.43)
a  = 2.12cm_1 ±0.24
The results of the power loss in the bacon as a function of bacon depth are shown in 
Figure 4.42. The curves showed that almost 90% of the incident microwave power 
was absorbed at the 4mm depth. Hence, at these microwave frequencies, the 
penetration depth is only limited to 4mm thickness.
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Figure 4.42 Power loss in the bacon as a function of bacon thickness.
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4.5.3 Attenuation against Frequency for Ham Tissue
Next, the analysis of attenuation in the ham was carried out and each slice of ham has 
an average thickness of 1mm. Figure 4.43 shows the attenuation in the ham as a 
function of frequency.
2.9
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—X—4mm (4 Slices)
Figure 4.43 Attenuation in the ham as a function of frequency.
The results of Figure 4.43 showed that the 1mm ham had a high power loss due to 
most microwave power being reflected. For increasing ham thickness, the reduction 
in power loss becomes less significant. The power reflected at the ham-air surface 
was calculated to be 91.8% of the incident microwave power.
The attenuation coefficient of a ham at 2.6GHz was calculated by using equation 
4.41, to be
P(0.1) = 0.0594 = (1-0.918) exp(-2 * 0.1 * a)
a  =1.612cm'1(±0.713)
The power loss in the ham as a function of ham depth was plotted in Figure 4.44. The 
curves showed that at least 90% incident microwave power was absorbed at 1mm.
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This analysis again showed that the penetration depth at these microwave frequencies 
is limited to 1mm thickness.
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Figure 4.44 Power absorbed in the ham as a function of ham thickness.
4.5.4 Summary of the Microwave System
The microwave system requires that the minimum dipole length to be half 
wavelengths for the resonance effect. The minimum dipole length for a 2.5GHz 
system is 6cm which is still an impractical size for embedded use. The analyses 
showed that the chicken skin, bacon and ham tissues have high attenuation losses at 
microwave frequencies. These findings suggest that increasing the coupling 
frequency could reduce the incident microwave’s penetration depth into tissue. The 
high energy absorption in tissue and the high reflection losses at the surface are the 
main reasons that the microwave radiative coupling principle is not an efficient 
method for energy transfer. The microwave system evaluation concludes that the use 
of microwave system to couple energy into tissue is not suitable for embedded 
photodynamic therapy because there is insufficient microwave energy penetrates 
deep enough into tissue for any significant energy coupling.
125
5. Computational Study
CHAPTER 5 COMPUTATIONAL STUDY
This chapter describes the procedures for running and optimising die TODDY 
computer model to investigate the absorption of light in two-dimensional model of 
tissue. The parameters needed to control the simulation were described in detail. A 
tumour was modelled as a single layer between the upper dermis and lower dermis. 
The second part describes the predicted temperature rise in tumour as a result of the 
absorption of photons in tissue and the subsequent photothermal damage arises from 
temperature increase. The final part describes the amount of photodynamic damage 
that occurs in the tissue. A number of radiation and photodynamic parameters were 
analysed and evaluated in order to optimise the ideal conditions to cause maximum 
damage to the tumour and minimise damage to the surrounding normal tissue.
5.1 TODDY Model G.U.I.
The TODDY model graphic user interface (G.U.I.) is the link between the user and 
the program. It enables the user to input the tissue geometry and to set parameters for 
the Monte Carlo, thermal and damage calculations and finally show the results as 
colour-coded intensity profiles after the calculations were completed.
5.1.1 Reference Model Properties
The grid dimension of 400 x 400 cells was used in the model. The fine grid 
dimension was chosen to have a more accurate representation of the results. This 
gives a total number of 160,000 cells in the Monte-Carlo computational space. The 
total number of photon count used for the study was 250,000. It is best to use the 
highest photon count as possible so that the result of photon absorption in tissue 
becomes consistent at each simulation run in order to ensure statistical convergence.
The reference tissue model (Figure 5.1) consists of
- 1 0 0 pm thick epidermis layer
- 3000pm thick upper dermis
- 4000pm thick lower dermis
- 1 0 0 0 pm thick x 1 0 0 0 pm width tumour located in the lower dermis
- 1 0 ,0 0 0 pm tissue width
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Figure 5.1: Reference tissue model
5.1.2 Optical, Thermal and Photodynamic Properties
The standard optical, thermal and photodynamic properties for the reference tissue 
model were summarised and listed in Table 5.1 - 5.6. These standard properties were 
used in the following computational analyses unless otherwise stated.
Wavelength 630nm LED Depth 2600pm
Pulse time 300ps Fluence 2.5 Jem'2
Beam diameter 5 mm Time step 1.0 e-6
Table 5.1: Light parameters
Tissue PaCcm'1) PsCcm'1) g
Epidermis 0.18 580.00 0.789
Melanin 345.83 34.58 0.789
Dermis 2.29 225.00 0.789
Tumour (Blood) 159.06 468.00 0.980
Table 5.2: Tissue optical properties at 585nm wavelength
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Tissue M-aCcm'1) M-s (cm'1) g
Epidermis 0.18 580.00 0.789
Melanin 308.33 30.83 0.789
Dermis 2.18 2 2 0 . 0 0 0.789
Tumour (Blood) 3.17 468.00 0.980
Table 5.3: Tissue optical properties at 630nm wavelength
Tissue PaCcm'1) Ms (cm'1) g
Epidermis 0.18 580.00 0.789
Melanin 270.00 27.00 0.789
Dermis 2 . 1 2 217.00 0.789
Tumour (Blood) 1.85 468.00 0.980
Table 5.4: Tissue optical properties at 652nm wavelength
Tissue K(W m'IOC'1) p(kgm'3) CKJkg'1)
Epidermis 1.06 1050 3350
Dermis 1.06 1050 3350
Tumour (Blood) 0.62 1 0 0 0 3500
Table 5.5: Tissue thermal properties
Damage rate constant (kpd) 0 . 0 0 1
Photobleaching rate constant (kPb) 0.00025
Tissue perfusion rate constant (kperf) 0 . 0 1
Oxygen removal rate constant (koxy) 1 . 0
Oxygen concentration in tissue 1 . 0
Photosensitiser concentration in tumour to normal 
tissue (Contrast ratio)
0.67/0.33 (2:1)
Table 5.6: Photodynamic properties
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5.1.3 Melanin Distribution
The absorption in the epidermis is usually dominated by melanin absorption in most 
individuals. The actual net epidermis absorption combines the baseline epidermis 
absorption and the melanin absorption. The melanin distribution used in the 
reference epidermis layer was based on die G. Daniel and K. Donne single epidermal 
layer model with die melanin concentration distributed according to the normal skin 
type as shown in Figure 5.2. 1931
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Figure 5.2: Melanin distribution in the epidermis layer
5.2 Effects of LED Depth in the Tissue at 585nm
The light source can be positioned in the centre of the tissue at various depths to 
model an LED embedded subcutaneously into tissue. To investigate the benefits of 
using an embedded light source in PDT, the position of the LED in relation to tissue 
depth was varied in the model. The photons were then launched at the centre of 
tissue from the depth of the LED. The reference tissue model and standard optical, 
thermal and photodynamic properties at 585nm were used in the following analyses.
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5.2.1 Light Absorption against LED Depth
The LED depths were varied in the steps of 600pm from 0pm up to 3000pm. Figure 
5.3 shows the light absorption profiles in tissue at each step as the LED was 
positioned between 0pm to 3000pm tissue depth. The results of Figure 5.3 show that 
the light distribution penetrates deeper into tissue as the LED position was moved 
closer to the tumour. The maximum photon absorption in the tumour was achieved 
when the LED was positioned near to the tumour. It is interesting to note the low 
photon absorption in the centre of the tumour. Figure 5.4 shows the percentage of 
energy being absorbed in tumour and upper dermis for an LED depth ranging from 
0pm to 3000pm. The curve shows that the energy being absorbed in a tumour 
increases gradually with the LED depth. It can be seen that at 3000pm LED depth, 
the percentage of total photons being absorbed in the tumour was highest at 42.72%. 
The energy absorbed in the upper dermis starts to decrease at 1200pm LED depth in 
tissue as the LED was located far from the epidermis. When the LED was placed far 
from the tumour, the percentage of total photons being absorbed in the tumour 
reduces to 13.2% at 1200pm LED depth. In fact, an LED placed at the surface of 
epidermis generates the lowest deposited photon in tumour of 1.48%. A high 
percentage of the photons were being backscattered out of tissue. In addition, the 
presence of melanin in the lower part of the epidermis causes a higher photon 
absorption in the epidermis layer of 19.83%. These findings show that an LED 
positioned near to the tumour has the maximum energy absorption in the tumour and 
lowest energy absorption in the upper dermis. For PDT treatment, it is desirable to 
achieve maximum photon absorption in the tumour with minimum energy absorption 
in the normal tissues, to enhance the efficiency of PDT and to minimise damage to 
the surrounding tissues. For this reason, the suggested depth for the LED placement 
is 80% of the tumour depth in tissue. The photon energy absorption versus the 
tumour thickness in the cross section of the tumour for an LED depth at 0pm, 
1000|nm, and 2600pm was shown in Figure 5.5. The result shows that almost all of 
the photons energy was being absorbed in the tumour by a 600pm tumour thickness. 
The energy deposited in the tumour drops rapidly with tumour thickness. This is 
because the tumour has a high optical absorption coefficient and a high anisotropy 
factor value. Hence, the light was highly attenuated as it penetrates the deepest
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tumour layer. Beyond 600pm thickness, the energy absorbed was mainly from 
photons scattering in the lower dermis. These findings show that the deposited 
energy in the tumour was a lot higher at 2600pm tissue depth compared to 0pm and 
1000pm tissue depth.
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Figure 5.3: Light absorption profiles for various LED depths (L.D) from Opm 
to 3000pm in tissue at 585nm wavelength.
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Figure 5.4: Energy absorbed in epidermis, upper dermis layer and tumour 
layer as a function of the LED depth in tissue.
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Figure 5.5: Deposited energy per unit volume vs. tumour thickness of the cross
section of the tumour for the LED depth at Opm, 1000pm and 2600pm.
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5.2.2 Temperature against LED Depth
To determine the effects of LED position on the temperature rise in a tumour, a high 
fluence of 2.5Jem' was used in this analysis. The maximum temperature in the 
tumour and middle point of the tumour was plotted in Figure 5.6. The curve in Figure
5.6 show that the maximum temperature in the tumour increases rapidly with the 
LED depth. There is only a small increase of the temperature in middle point of the 
tumour due to low energy absorption in the centre of the tumour. The highest 
temperature in the tumour was achieved as the LED was placed near to the tumour.
max tumour
)0 1500 20
LED depth in tissue (um)
Figure 5.6: Temperature rise in the tumour and middle point of the
tumour as a function of the LED depth in tissue.
5.2.3 Photothermal Damage against LED Depth
It was assumed here that at temperatures of 45°C and above, the tumour was 
damaged by hyperthermia corresponding to the photothermal damage scale of 1.0 
and above. This assumption is valid only for the standard short pulse duration. The 
total photothermal damage in tumour as a function of LED depth in tissue was 
plotted in Figure 5.7. The results show that photothermal damage increases with the
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LED depth. The amount of photothermal damage was approximately proportional to 
the temperature rise in the tumour.
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Figure 5.7: Total photothermal damage in the tumour as a function of 
the LED depth in tissue.
The photothermal damage profiles in the tumour for an LED positioned between 
Opm to 3000pm tissue depth were shown in Figure 5.8. At 0pm tissue depth, there 
was not enough energy absorption to cause any substantial photothermal damage in 
the tumour. The highest profile of photothermal damage arises when the LED was 
placed in 3000pm tissue depth. However, the maximum damage occurs mostly in the 
top wall of the tumour as seen at 3000pm LED depth in tissue. These results once 
more show that the LED positioned near to the tumour generates the maximum 
photothermal damage in the tumour.
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Figure 5.8: Photothermal damage profiles for various LED depths (L.D.) 
from Opm to 3000pm in tissue at 585nm wavelength.
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5.2.4 Photodynamic Damage against LED Depth
Figure 5.9 below shows the total photodynamic damage in a tumour as a function of 
the LED depth in tissue. The amount of photodynamic damage rise greatly with LED 
depth in tissue from Opm to 1200pm. When the LED was placed beyond the 1200pm 
tissue depth, the damage starts to saturate and slowly increases. The photodynamic 
damage profile in the tumour varies along the LED depth in tissue as shown in 
Figure 5.10. The photodynamic damage in tissue has a wider and more uniform 
distribution as the LED was positioned closer to the tumour.
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Figure 5.9: Total photodynamic damage in the tumour as a function 
of the LED depth in tissue.
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Figure 5.10: Photodynamic damage profiles for various LED depths (L.D.) 
from Oum to 3000um in tissue at 585nm wavelength.
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5.2.5 Conclusions
All of these analyses above suggest that when an embedded light source was placed 
near to the tumour, maximum photon energy will be absorbed in the tumour region. 
This gives a higher light penetration depth into tissue at the same wavelength. Also, 
die epidermis layer absorbs less photons and almost all die emitted energy was 
contained inside the tissue. The temperature in the tumour increases and has an effect 
on the maximum photothermal damage in the tumour. The tumour achieves 
maximum photodynamic damage in the entire tumour region. In contrast, the 
maximum photodynamic damage only occurs in the epidermis layer and in the top 
wall of the tumour for surface light source. This proves that an embedded light 
source offers a better PDT response compared to conventional surface light source.
141
5. Computational Study
5.3 Effects o f W avelength Selection
In this section, the effect of the light source wavelength on the light absorption 
distribution and photodynamic damage profile in the tumour was considered. Three 
wavelengths - 585nm, 630nm, and 652nm - were chosen to show the benefits of 
using shorter or longer wavelengths. The reference tissue model and standard optical, 
thermal and photodynamic properties were used in the following analyses.
5.3.1 Light Absorption Profile against Wavelength
At a 585nm wavelength, the percentage of photons being absorbed in the tumour was 
32.45% (Figure 5.11). For a longer wavelength of 630nm, the percentage of total 
photons being absorbed in the tumour reduces to 5.34%, as shown in Figure 5.12. 
Figure 5 .13 shows the percentage of total photons being absorbed in the tumour drop 
further to 3.37% at 652nm wavelength. The light distribution for both 630nm and 
652nm wavelengths were much more uniform inside and around the tumour layer.
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Figure 5.11: Light absorption profile at 585nm wavelength
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Figure 5.12: Light absorption profile at 630nm wavelength
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Figure 5.13: Light absorption profile at 652nm wavelength
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Figure 5.14 and Figure 5.15 show the energy deposition in the cross section of a 
tumour for 585nm, 630nm and 652nm wavelengths. There was a significant 
difference in the total amount of energy absorbed between 585nm with 630nm and 
652nm. This was because at 585nm, the absorption coefficient for the tumour was 
much higher compared to 630nm and 652nm. Light was highly attenuated and the 
photon energy drops off rapidly with increasing in tumour depth. Whereas, at 630nm 
652nm, the deposited energy pattern was more consistent on all tumour thickness. At 
a longer wavelength, the penetration depth of light was much higher, which leads to 
a more uniform absorption profile compared to 585nm wavelength. This explains 
why the majority of photosensitisers in the market have absorption wavelength in the 
red region. When comparing the difference between 630nm and 652nm wavelengths, 
the energy deposition at 630nm was slightly higher by 20% than the energy 
deposition at 652nm. This was because the variation in the absorption coefficient for 
both wavelengths was small. Shorter wavelengths generate a higher energy 
deposition of the photons. Conversely, longer wavelengths carry lower energy with 
less of the thermal effect and deeper photodynamic effect. To achieve deeper 
penetration of light into the tumour and uniform distribution in foe tumour, it is 
suggested that both wavelengths 630nm and 652nm are more suitable for PDT 
application. The wavelength selection between 630nm and 652nm is dependent upon 
foe photosensitiser used for PDT. The peak wavelengths for Photofrin and m-TPHC 
photosensitiser are 630nm and 652nm respectively. When foe photon wavelength 
matches foe peak wavelength in which foe photosensitiser absorption coefficient is at 
its peak point, foe efficiency of generation and damage by singlet oxygen could be 
greater. Thus, for m-TPHC photosensitiser, foe 652nm wavelength is a much better 
choice for PDT, although foe 630nm wavelength offers a higher energy deposition in 
foe tumour layer compared to 650nm.
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Figure 5.14: Deposited energy per unit volume vs. tumour depth of the cross 
section of the tumour for 585nm, 630nm and 652nm wavelengths.
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Figure 5.15: Detailed comparison of deposited energy per unit volume for 630nm 
and 652nm wavelengths.
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5.3.2 Temperature against Wavelength
Next, the peak temperatures in tissue for 585nm, 630nm and 652nm wavelengths 
were simulated. High fluence of 2.5 Jem'2 was used in this study. The end results of 
the temperatures in different layers of tissue were listed in Table 5.7.
Wavelength Skin surface 
temp ( °C)
Upper dermis 
temp ( °C)
Tumour core 
temp ( °C)
Tumour wall 
temp ( °C)
585nm 35.11 35.23 35.53 45.01
630nm 35.15 35.30 35.49 35.44
652nm 35.14 35.30 35.32 35.59
Table 5.7: Peak temperatures in the different layers of tissue at 51S5nm, 630nm
and 652 wavelengths.
The tumour wall temperature was much higher at 585nm than at 630nm and 652nm 
wavelengths. The temperature difference between the tumour core and the tumour 
wall noted at 585nm wavelength was due to higher energy absorption at the tumour 
wall. At red region wavelengths, the temperature rise was much the same in the 
tumour core and the tumour wall.
5.3.3 Photothermal Damage against Wavelength
In the previous section, it was observed that the 585nm wavelength produces the 
highest temperature rise in the tumour wall. Table 5.8 shows the total photothermal 
damage attainable in the tumour.
Wavelength Total photothermal damage in the tumour
585nm 4805.470
630nm 3915.805
652nm 3867.091
Table 5.8: Total photothermal damage in the tumour at 585nm, 630nm and 652
wavelengths
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At 585nm wavelength, almost all of the total damage occurs mostly in the tumour 
wall with no significant damage in the tumour core, as shown in Figure 5.16. At 
630nm and 652nm wavelengths, the photothermal damage in the tumour does not 
exist, as it was below the lower limit damage of 4000 for the tumour cells, hence, no 
figures were shown.
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Figure 5.16: Photothermal damage profile at 585nm wavelength.
5.3.4 Photodynamic Damage against Wavelength
Next, the effect of each different wavelength on the photodynamic damage was 
examined. The total photodynamic damage occurred in the tumour was highest at 
630nm wavelength among the three wavelengths as listed in Table 5.9.
Wavelength Total photodynamic damage in the tumour
585nm 9890.630
630nm 10607.291
652nm 10417.248
Table 5.9: 1fotal photodynamic damage in the tumour at 585nm, 630nm and
652nm wavelengths
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However, the photodynamic damage profile in tissue varies with wavelength. It is 
shown in Figure 5.17, that not every section of the tumour receives maximum 
photodynamic damage at 585nm wavelength. The maximum damage was limited to 
the tumour core only when compared to 630nm and 652nm wavelengths. For 630nm 
and 652nm, the profile of photodynamic damage was more uniform in the tumour 
region as shown in Figure 5.18 and Figure 5.19. Also at these wavelengths, the light 
penetrates deeper into tissue and this generates a higher damage in the lower dermis.
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Figure 5.17: Photodynamic damage profile at 585nm wavelength
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Figure 5.18: Photodynamic damage profile at 630nm wavelength
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Figure 5.19: Photodynamic damage profile at 652nm wavelength 
5.3.5 Conclusions
The analyses of wavelength selection demonstrate that at a longer wavelength or the 
red region, the penetration of light into tissue was higher than the yellow region. This 
gives a lower and more uniform energy absorption in the tumour area. The photon 
absorption was sufficient to produce a uniform photodynamic damage profile in the 
tumour with minimum temperature rise and maximum photothermal damage in the 
tumour. An important consideration in the wavelength selection is that the light 
source wavelength matches the photosensitiser peak wavelength for maximum 
absorption and generation of cytotoxic singlet oxygen. The red region wavelengths 
are well suited for the peak wavelength of the majority of photosensitisers used in 
PDT. Hence, it is suggested that the wavelengths in the red region have a much better 
PDT efficiency compared to shorter wavelengths.
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5.4 Effects of Fluence Selection
The source power for the embedded light source comes from inductive coupling 
method. Consequently, the light source’s energy output can be controlled by the 
amount of RF energy transmitted into tissue.
To investigate the effects of fluence against the photothermal damage and 
photodynamic damage in the tumour, the light source’s fluence was varied from 
0.005 Jem"2 to 6.0 Jem"2 as shown in Table 5.10. These fluence ranges were selected 
to reproduce the energy of low, medium and high intensity light through a 5mm 
beam spot. The irradiation duration was kept constant for the equivalent fluence 
range tested. The reference tissue model and standard optical, thermal and 
photodynamic properties at 630nm were used in the following analyses.
Fluence (Jem"2) Light energy (m Js1) Intensity
0.005 1.0 Low
0.05 9.8 Low
0.5 98.4 Low
1.0 196.4 Medium
2.0 392.3 Medium
3.0 589.1 High
6.0 1178.0 High
Table 5.10: Fluence with the equivalent light energy and intensity
5.4.1 Temperature against Fluence
The maximum temperatures in the tumour for fluence range between 0.005 Jem"2 to
6.0 Jem'2, were plotted in Figure 5.20. The linear line plot in Figure 5.20 shows that 
the temperature rise in the tumour was proportional to the fluence of the light source. 
Even at the highest fluence, the maximum temperature increase in the tumour was 
only limited to 1.4 °C.
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Figure 5.20: Maximum temperature in the tumour as a function of fluence.
5.4.2 Photothermal Damage against Fluence
Next, the effect of temperature rise in previous section on the photothermal damage 
was examined. The maximum photothermal damage in the tumour for the fluence 
range was plotted in Figure 5.21.
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Figure 5.21: Total photothermal damage in the tumour as a function of fluence.
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The amount of photothermal damage increases by a small amount throughout the 
fluence range. This is because the temperature rise in the tumour was too low to 
cause any substantial photothermal damage.
5.4.3 Photodynamic Damage against Fluence
The effects of fluence on the photodynamic damage were investigated in this 
subsection. The maximum photodynamic damage in the tumour as a function of 
fluence was plotted in Figure 5.22.
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Figure 5.22: Total photodynamic damage in the tumour as a function of fluence.
It can be seen from Figure 5.22 that the highest photodynamic damage occurs when 
the fluence was 2.0 Jem '. The photodynamic damage increases rapidly at low
9  9fluence range (0-1 Jem ') and starts to saturate at medium fluence range (1-3 Jem '). 
At low fluence of 0.5 Jem'2, the photodynamic damage achieves at least 80% 
efficiency of the peak photodynamic damage. The saturation effect of photodynamic 
damage observed in the medium fluence range is as a result of limited photosensitiser 
concentration in the tumour being exhausted. Saturation decreases the photodynamic
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effectiveness by limiting the rate of photodynamic damage to a maximum value. 
Although it can be seen as a disadvantage, the benefit of saturation is that the 
photodynamic effect is only dependent on the concentration of the photosensitiser 
and not on the fluence. This suggests that pulsing may be advantageous in 
repopulating the photosensitiser in the tumour. It is interesting to note that at high 
fluence range (3-6 Jem*2), there was a slight reduction in the photodynamic damage. 
A reasonable explanation for this is that high fluence increases the rate of 
photobleaching in the tumour. At high fluence, photobleaching would prevent 
administration of light dose sufficient for complete tumour damage. Thus, low 
fluence may be necessary to achieve an equivalent photodynamic effect when lower 
photosensitiser doses were used. Figure 5.23 shows that photodynamic damage 
profile varies with fluence range between 0.005 Jem* to 6.0 Jem*. From the results 
of Figure 5.23, 0.5 Jem'2 fluence was enough to generate 80% PDT effectiveness 
with the advantage of minimum damage in the upper dermis and lower dermis as 
compared to 2.0 Jem'2 fluence.
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Figure 5.23: Photodynamic damage profile for fluence range between 
0.005 Jem'2 to 6.0 Jem'2.
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5.4.4 Photosensitiser Concentration against Fluence
Next, the effects of fluence on the rate of photosensitiser concentration consumption 
and the rate of photodynamic damage in the tumour were analysed. Figure 5.24 
shows the photodynamic damage and photosensitiser concentration in the tumour as 
a function of time for 0.5 Jem'2, 1.0 Jem'2 and 3.0 Jem 2 fluence. It can be seen at 
high fluence that the photodynamic damage in the tumour reaches saturation point in 
the shortest duration as the photosensitiser concentration in the tumour was expended. 
At medium fluence, the rate of photodynamic damage was slower than high fluence 
but faster than low fluence. Although the rate of photodynamic damage at low 
fluence was the slowest among all, it still reaches the peak photodynamic damage 
level of high fluence at the expense of longer irradiation duration. This has an added 
benefit of maintaining a high level of oxygen concentration in the tumour throughout 
the irradiation duration.
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Figure 5.24: Photosensitiser concentration with normalised photodynamic 
damage in the tumour as a function of irradiation time.
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5.4.5 Conclusions
These findings suggest that low fluence outcome was just as effective as medium 
fluence and high fluence. To avoid thermal effects, the fluence should be kept below 
the photothermal damage lower threshold. This opens up the possibility of using a 
low intensity LED embedded into tissue for PDT. However, the total light dose 
required for PDT is high hence time of treatment will be longer if low fluence is used. 
Thus, an example of using m-THPC as a photosensitiser in cancer treatment, die total 
light dose may typically be 100.0 Jem-2 and die fluence is 0.5 Jem-2. The time of 
treatment required is therefore 200 seconds (100/0.5) or just over three minutes. If 
the fluence of 0.05J/cm2 is used, the time of treatment required is 2000 seconds or 34 
minutes. The embedded LED can be programmed to pulse continuously to deliver 
die minimum total light dose required and then switched off. The inactivated LED is 
left inside tissue for subsequent treatment. This method allows PDT to be repeated as 
many times as needed at intervals of two weeks to completely destroy the tumour 
while maintaining the PDT efficiency at each treatment.
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5.5 Effects of Photosensitiser and Oxygen Concentration
In this section, the importance of photosensitiser concentration and oxygen 
concentration in the normal and tumour tissue were demonstrated. The ratio of 
photosensitiser intake in the tumour tissue compared to the normal tissue determines 
the selectivity of photodynamic damage in tissue. The oxygen concentration in tissue 
governs the amount of photodynamic effect occurring at that time. These two key 
parameter values were varied and analysed in the following subsections.
5.5.1 Photodynamic Damage against Photosensitiser Contrast Ratio
The ratio of photosensitiser intake in tumour and normal tissue for different types of 
photosensitiser were listed in Table 5.11. The photosensitiser initial total dose in 
tissue were normalised to a value of 1.0.
Photosensitiser Ratio of photosensitiser 
intake in tumour/normal 
tissuet73]
Concentration of photosensitiser 
in tumour/normal tissue 
(Total dose of 1.0)
Photoffin 0.3:1 0.23/0.76
AlPCTrS 1:1 0.5/0.5
HPD (1) 1.7:1 0.63/0.37
Chi e6 6.3:1 0.86/0.14
HPD (2) 8.9:1 0.9/0.1
Table 5.11: Ratio of photosensitiser intake in the tumour and normal
tissue for various photosensitisers
The amount of photodynamic damage in the tumour and in the dermis as a function 
of photosensitiser concentration in the tumour was plotted in Figure 5.25. The 
photodynamic damage profiles for each photosensitiser ratio of intake were shown in 
Figure 5.26 to Figure 5.30. It can be said that the minimum concentration required 
for photosensitiser localisation in the tumour was 60% of the total dose or the ratio of 
1.5:1 to improve the selectivity of photodynamic effect in the tumour. The ratio of 
8.9:1 of HPD (2) intake achieves the best tumour selectivity along with the highest 
photodynamic damage in the tumour.
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Figure 5.25: Photodynamic damage in the tumour and in the dermis as a 
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Figure 5.26: Photodynamic damage profile for 0.3:1 ratio of photosensitiser
intake in tumour tissue and normal tissue.
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Figure 5.27: Photodynamic damage profile for 1:1 ratio of photosensitiser intake 
in tumour tissue and normal tissue.
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Figure 5.29: Photodynamic damage profile for 6.3:1 ratio of photosensitiser 
intake in tumour tissue and normal tissue.
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Figure 5.30: Photodynamic damage profile for 8.9:1 ratio of photosensitiser
intake in tumour tissue and normal tissue.
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5.5.2 Photodynamic Damage against Photosensitiser Dose
Next, the effects of photosensitiser dose on the photodynamic damage in the tumour 
were examined. The photosensitiser initial total dose was varied to reflect the high 
photosensitiser dose and low photosensitiser dose applied in the PDT. The ratio of 
2:1 of photosensitiser intake in the tumour and normal tissue was used in the analysis. 
Table 5.12 shows the percentage of photosensitiser dose with the photosensitiser 
concentration in the tumour and normal tissue.
Percentage of 
control dose
Normalised 
photosensitiser dose
Concentration of photosensitiser 
in tumour/normal tissue
200% 2.0 1.33/0.67
150% 1.5 1.0/0.5
100% 1.0 (control dose) 0.67/0.33
50% 0.5 0.33/0.17
25% 0.25 0.17/0.08
0% 0 0/0
Table 5.12: Photosensitiser dose with photosensitiser concentration in the 
tumour/normal tissue
The results of Figure 5.31 show that the increase in photodynamic damage in the 
tumour was proportional to the photosensitiser concentration in the tumour. When 
the photosensitiser dose was doubled, the damage in the tumour increases 
correspondingly. Moreover the photodynamic damage in the surrounding tissue also 
increases relatively. When there was no photosensitiser dose absorbed, the damage 
occurring in the tumour and normal tissue was zero. These findings confirm that the 
photosensitiser dose used for PDT should be just adequate for tumour annihilation. 
An increase in photosensitiser dose does not help the selective photodynamic effect 
in the tumour.
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Figure 5.31: Photodynamic damage in the tumour and dermis as a function of 
photosensitiser dose
5.5.3 Photodynamic Damage against Oxygen Concentration
To help show the importance of oxygen in effect to the photodynamic effect, the 
initial oxygen concentration in the tumour was varied according to the percentage of 
oxygenation in the tumour. Table 5.13 shows the percentage of oxygenation in the 
tumour with the oxygen concentration in the tumour.
Figure 5.32 shows the amount of photodynamic damage in the tumour as a function 
of oxygen concentration in the tumour. It can be seen in Figure 5.32 that the 
photodynamic damage in the tumour increases with increasing oxygen concentration 
in the tumour. When there was no oxygen available, the damage occurring in the 
tumour was zero. It is best to increase the amount of oxygen available to the tumour 
for maximum photodynamic effect. The amount of oxygen available to the tumour is 
dependent on the percentage of oxygenation in the blood and tissue perfusion rate. 
Oxyhemoglobin blood carries a higher percentage of oxygen level than 
deoxyhemoglobin blood. Increasing the tissue perfusion rate also helps replacing the 
oxygen lost during irradiation and maintaining the initial oxygen level in the tumour.
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Percentage of oxygenation in the 
tumour
Equivalent initial oxygen 
concentration in the tumour
100% 1.0
90% 0.9
80% 0.8
70% 0.7
60% 0.6
50% 0.5
40% 0.4
30% 0.3
20% 0.2
10% 0.1
0% 0
Table 5.13: Percentage of oxygenation in the tumour with oxygen concentration 
in the tumour
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Figure 5.32: Photodynamic damage in the tumour as a function of oxygen
concentration for constant perfusion rate
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5.6 Sensitivity Analysis of Photodynamic Reaction Rate Constants
5.6.1 Damage Rate Constant (kpd) Variation
The role of damage rate constant combines the photosensitiser absorption coefficient 
and the efficiency of generation of cytotoxic oxygen species. This is dependent on 
the light’s wavelength and photosensitiser used for PDT treatment. The quantity of 
damage rate was varied to demonstrate the efficiency of the photosensitiser with 
effect to the photodynamic damage as shown in Table 5.14.
Percentage of damage rate kpd
200% 0.002
150% 0.0015
100% 0.001 (control constant)
50% 0.0005
25% 0.00025
1% 0.00002
Table 5.14: Percentage of camage rate with kpd quantity
The results of photodynamic damage in the tumour as a function of damage rate 
variation were plotted in Figure 5.33. The graph in the Figure 5.33 shows that the 
increase in photodynamic damage in the tumour is proportional to the efficiency of 
the photosensitiser. The efficiency of various photosensitisers in generating singlet 
oxygen is dependent on the singlet oxygen quantum yield. This means that a high 
singlet oxygen quantum field photosensitiser should be used to produce singlet 
oxygen for maximum photodynamic effect. Furthermore, high photodynamic 
damage rate is achieved if the wavelength of the light source matches the 
photosensitiser peak wavelength. When the absorption coefficient is at the peak level, 
the efficiency of generation of oxygen radical is higher than any other wavelengths 
used. Overall, the photosensitiser dose used in the PDT can then be reduced to 
generate the same amount of photodynamic damage with the added benefit of less 
photosensitivity endured by the patients.
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Figure 5.33: Photodynamic damage in the tumour as a function of damage rate
5.6.2 Photobleaching Rate Constant (kpb) Variation
Next, the effect of photobleaching rate on the photodynamic damage in the tumour 
was examined. The rate of photobleaching of various photosensitisers is dependent 
on the photobleaching quantum yield. The initial photobleaching rate was varied as 
listed in Table 5.15.
Percentage of photobleaching rate kpb
200% 0.00050
150% 0.000375
100% 0.00025 (control constant)
50% 0.000125
25% 0.0000625
1% 0.0000025
Table 5.15: Percentage of photobleaching rate with kpb quantity
Figure 5.34 show the photodynamic damage in the tumour as a function of
photobleaching rate variation. The curve shows that, by decreasing the
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photobleaching rate, the photodynamic damage increases greatly in the tumour. It 
was observed that by reducing the photobleaching rate by half, the amount of 
photodynamic damage was doubled in the tumour. Hence, this finding shows that the 
use of a photosensitiser with low photobleaching quantum yields generates a better 
PDT response than a high photobleaching quantum yield photosensitiser.
0.00005 0.0001 0.00015 0.0002 0.00025 0.0003 0.00035 0.0004 0.00045 0.0005
Figure 5.34: Photodynamic damage in the tumour as a function of 
photobleaching rate
5.6.3 Tissue Perfusion Rate Constant (kperf) Variation
In this subsection, the effect of tissue perfusion rate on the photodynamic damage in 
the tumour was analysed. The initial tissue perfusion rate was varied as shown in 
Table 5.16. The results of photodynamic damage in the tumour as a function of tissue 
perfusion rate variation were shown in Figure 5.35. Increasing the tissue perfusion 
rate to 200% only increases the photodynamic effect by 1%. Also, when the tissue 
perfusion rate dropped to 50% of the initial value, the photodynamic damage 
decreased by 3%. This was mainly because the oxygen levels in the tumour and 
normal tissue were already at their peak level. The rate of photodynamic damage at 
medium fluence does not deplete the oxygen level to a great extent that the oxygen
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level remained high throughout the total irradiation duration. Hence, the increase or 
decrease in the tissue perfusion rate provides a small effect on the overall efficiency 
of the PDT treatment. In conclusion, all of the rate constant analyses were for the 
standard short pulse duration at medium fluence. For low fluence, the pulse time is 
much longer; therefore the variation of damage with the perfusion rate will be 
sensitive to the pulse length over which the damage was achieved.
Percentage of tissue perfusion rate kperf
200% 0.02
150% 0.015
100% 0.01 (control constant)
50% 0.005
25% 0.0025
1% 0.0002
Table 5.16: Percentage of tissue perfusion rate with kperf quantity
0.8
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0.4
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0.002 0.004 0.006 0.008 0.01 0.012 0.014 0.016 0.018 0.020
kprf
Figure 5.35: Photodynamic damage in the tumour as a function of tissue
perfusion rate
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5.7 Summary of Computational Study
A simple model of a light source embedded in tissue based on the Monte Carlo light 
transport was developed and used to study the light absorption distributions in tissue. 
In this chapter, it is shown that an embedded light source increases the total photon 
absorption being absorbed in the tumour. The LED position in tissue determines the 
amount of photon energy deposition in the tumour. The energy gained between 
surface light irradiation and light source placed next to the tumour was at least 40%. 
Another added benefit was that light absorption in the epidermis-melanin layer can 
be bypassed and reduced to almost zero when the LED was placed deep inside tissue. 
Also by using an embedded LED, the light penetration depth into tissue can be 
increased without the use of longer wavelengths. This generates higher temperature 
increase and photothermal damage in the tumour. The photodynamic induced 
damage in the tumour penetrates more deeply when the LED was placed near to the 
tumour.
The wavelength analyses showed that the use of longer wavelengths at 630nm and 
652nm were preferable than 585nm since these wavelengths offer deeper light 
penetration depth and match the peak wavelength of most photosensitisers. Also, the 
temperature rise in tissue was much lower and the photodynamic damage was more 
uniform in the entire tumour region.
In the fluence analyses, the use of low fluence photodynamic therapy has been 
shown to be as effective as high fluence. Low fluence does not generate any 
temperature rise and photothermal damage in tissue. The only disadvantage was that 
low fluence requires a longer treatment time than high fluence to offer maximum 
photodynamic damage for the same total light dose. However, low fluence does not 
consume photosensitiser or deplete oxygen as fast as high fluence. This maintains a 
high level of oxygen in tissue and provides a steady rate of photodynamic damage in 
the tumour.
The use of a photosensitiser with high ratio of photosensitiser intake in the tumour 
and normal tissue together with high singlet oxygen quantum yields and low
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photobleaching quantum yields achieves the maximum photodynamic damage and 
selectiveness in the tumour. Second generation photosensitisers offer better tumour 
selectivity and higher efficiency of singlet oxygen generation compared to first 
generation photosensitisers. Higher photosensitiser dose generates a higher 
photodynamic effect in the tumour but also in the normal tissue. Thus, the 
photosensitiser dose should be just sufficient for the total light dose to avoid 
photosensitivity experienced by patients after PDT treatment
The role of oxygen in tissue plays an important factor in the photodynamic process. 
Low oxygenation in tissue generates a lower photodynamic damage compared to 
high oxygen concentration. High tissue perfusion rate was favoured to replenish the 
oxygen depleted by photodynamic process during irradiation.
All of these findings showed that the use of an embedded LED with low fluence 
offers the possibility of continuous light pulsing (e.g. 2 seconds on and 1 second off) 
at low photosensitiser dose in favour for hours of uninterrupted photodynamic effect 
with the convenience of patients staying at home.
As for the accuracy of the model was concerned, the two dimensional model was 
only capable of predicting the amount of damage in the tumour and normal tissue 
based on the photodynamic parameters. The photosensitiser efficiency as well as the 
exact photosensitiser and oxygen concentration available at treatment site at the start 
of irradiation were arbitrary values used in the model. The real values of these 
quantities used in PDT would need to be inserted into the model for absolute values 
of damage to be estimated. However, the model clearly shows the benefits of using 
optimised values for the fluence and photodynamic properties. The computed 
photodynamic damage model needs to be calibrated to the clinical observation of 
tumour cell death in photodynamic therapy.
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CHAPTER 6 CONCLUSIONS
The review of the current literature indicated that photodynamic therapy is the 
emerging treatment of choice for a wide range of cancers. PDT is a complex 
photochemical process of light activation of photosensitiser in the presence of 
oxygen which generates the singlet oxygen excited state to cause damage in the cells. 
The Type II mechanism of action dominates the PDT process under normal oxygen 
concentration to generate the singlet oxygen to induce oxidative damage and cell 
necrosis. The selectivity of PDT is enhanced by the high contrast absorption of 
photosensitisers in the tumour and the confinement of the photosensitiser activation 
by controlling irradiation to only the tumour area.
The main setback for PDT extensive use is the costly and complex operation of laser 
systems. The disadvantages of photodynamic therapy are essentially the need for 
dedicated treatment rooms and the numerous treatment sessions to effectively kill the 
tumour. With high photosensitiser dose, a patient develops prolonged 
photosensitivity to visible light for several weeks following the PDT treatment. A 
significant point of the study is that photodynamic therapy is a photochemical 
reaction that is dependent on the total light dose and not the intensity of the light. 
Therefore, a low power LED system can be utilised as a cheaper method to treat 
cancer effectively. However, the low intensity irradiation of a LED system means 
that the light cannot penetrate the skin deeply to reach a deep centred tumour. The 
author’s hypothesis was to use a novel method, in which the light source is 
embedded subcutaneously into the tissue which is powered remotely by RF energy. 
The embedded device, when positioned correctly in the tissue, has the ability to focus 
light to the treated tumour area to increase the absorption of light in the tumour and 
to minimise damage to the surrounding tissue. This method increases the efficiency 
and selectivity of the photodynamic damage and, in effect, lower photosensitiser 
drug dose can be used. It is reviewed that for tumours to be completely destroyed, 
PDT needs to be repeated up to two or three times at intervals of three weeks to three 
months. With the embedded device, each treatment sessions can be done periodically 
with the convenience of patients treated at home. Patients are able avoid the 
photosensitivity to sunlight and artificial light by staying at home for several days
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after the treatment. This is a cost-effective technology that could enable the treatment 
of cancer to be available to a wider patient base.
A numerical model, written in Visual C++, has been developed to simulate photon 
transport and subsequent energy transfer in tissue. This model extends the previous 
TODDY computer model developed by G. Daniel and K. Donne by adding the 
chemistry kinetics of the photodynamic process as well as photothermal damage 
integration.[104] The theoretical computer model has shown that by positioning the 
LED next to the tumour, the absorption of light energy increased by 400% when 
comparing to surface irradiation. The embedded light source eliminated the light 
backscattered out of the tissues and reduced the absorption in the melanin layer. The 
low fluence delivered by a low energy light source is shown to be as effective as high 
fluence for photodynamic damage effect. The drawback with low fluence is 
essentially that the time of treatment required will be longer. However, at low 
fluence, the oxygen and photosensitiser can be replenished during the irradiation 
period to achieve optimum photodynamic effect. Second generation photosensitisers 
that have higher contrast ratio of absorption in the tumour relative to normal tissue 
combined with the LED wavelength selection achieves the best selectivity 
photodynamic damage in the tumour. It is also been shown that increasing the 
oxygen level and the tissue perfusion rate in the tissue increases the photodynamic 
damage effect.
The technique of using and embedded light source requires an energy source to 
power the LED. Obviously, a battery can be used but the main drawbacks with 
batteries are the size, limited power and toxicity. The author’s hypothesis was to use 
electromagnetic waves as a method for energy transfer into tissues. There are two 
possible methods, namely the inductive coupling method and the radiative coupling 
method. Inductive coupling system operates at 10 MHz - 30 MHz radio frequency 
with magnetic field as the medium of transfer, while radiative coupling system 
operates at 2 GHz -10 GHz microwave frequency with electric field as the medium 
of transfer. Inductive coupling is based on the loop coils and radiative coupling is 
based on the antennas such as dipoles.
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The absorption of electromagnetic wave energy in the tissue is dependent on the 
dielectric properties of tissue. On examination of the dielectric properties, the 
conductivity of the tissues increases with the wave frequency. At microwave 
frequency, the conductivity of the tissues is very high and exhibits high attenuation 
of energy in the tissues. The theoretical wave model showed that for 10 GHz 
frequency, half of the microwave energy is reflected out of the skin and only 5% of 
the incident power is available at 1cm tissue depth. The energy loss from reflection is 
due to the difference in the permittivity of free space and relative permittivity of the 
tissue. Hence, the microwave energy cannot penetrate deeply into tissue because of 
high attenuation loss. This has been confirmed experimentally with the microwave 
system operating at 2.5 GHz -  3.0 GHz using chicken skin, bacon and ham tissues. 
High energy absorption in tissues together with high reflection losses, are the main 
reasons that the radiative coupling method is not efficient for energy transfer. This is 
also the reason that the microwave frequency is employed in high power microwave 
oven for heating food.
As the inductive coupling method relies on magnetic field for energy transfer, an 
interesting point is that the permeability of tissue is the same as the permeability of 
free space. Hence the magnetic field can penetrate deep into human tissues with little 
attenuation and reflection losses. This is useful in coupling the energy needed to 
power the embedded device. This method of inductive coupling has been verified 
experimentally with the RF system operating at 13.56MHz. The RF system has been 
shown to induce the required voltage to power the LED in the receiver device 
successfully through the thick slices of bacon tissue. The receiver device showed no 
power loss when the energy is coupled into the bacon tissue. It is crucial that the 
circuit of the receiver is tuned to the resonant frequency of the transmitter. A tuned 
resonant circuit of the receiver generates a higher current to the LED. A higher 
number of coil turns and optimum diameter of the transmitter coil generate 
maximum magnetic field and concentrate the magnetic flux density into the receiver 
coil. When the operating frequency of the RF transmitter is increased, fewer coils are 
needed for the receiver which effectively reduces the size of the receiver. It is 
suggested that the 27MHz is another possible International Standard Medical 
frequency for energy transfer with the advantage of a smaller receiver size. In 
comparison with the microwave system, the RF system utilising inductive coupling
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method is a more efficient way to couple energy through the tissue to power the LED 
device.
The initial objective for undertaking this work, namely developing an innovative and 
effective method for improving the current PDT treatment modality, has been 
achieved.
6.1 Future work
Future possibility of work to continue this programme will concentrate on the 
following area.
• Developing a small scale integrated chip device incorporating the inductor, 
the capacitor and the LED.
• Production of a complete RF system capable of allowing investigation into a 
set of RF parameters allowing optimum energy coupling into tissue.
• Investigating a suitable method to implant the device into tissue easily and 
safely.
• Investigating a suitable method to accurately quantifying the photodynamic 
damage occurring in the tumour after treatment for clinical trial test.
• Developing a suitable method for doctors to assess the improvement of
treatment in the patients using the embedded light source for PDT.
• Improving theoretical computer models to include more complex tissues
geometries and modelling the light and photodynamic process more
accurately.
• Investigating other potential applications of an embedded light source in the 
medical field. Examples are low power bio-stimulation for wound healing 
and phototherapy for inflammation of subcutaneous tissue using red and blue 
LED.
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and/or duration of the radiation emitted from the source which Is internally Implanted in tissue adjacent to the 
target bone and illuminating it in a controlled regime comprising at least one period of illumination. The 
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emitted In pulses. The apparatus may comprise a power source 10. connected to the Implanted radiation 
source. Other embodiments specify that the radiation source and control means are both implanted, or the 
radiation source, control and a power source be implanted. The Implanted device may be powered by 
converting electromagnetic signals received 9, from outside the body 7,8, into electricity. Methods of 
implanting and using the device are described.
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METHOD AND APPARATUS FOR INTERACTING WITH BONE TISSUE USING
ILLUMINATING RADIATION
Description of W003002201
Method and apparatus for interacting with bone tissue using illuminating radiation
The present invention relates to a method and apparatus for interacting with bone tissue using illuminating radiation.
Many bone disorders, such as osteoporosis, lead to degradation of bone structure and strength. Thus, a treatment 
which results in new bone being formed at the treatment site may improve bone integrity and relieve disease 
symptoms.
Bone mainly consists of collagen and calcium deposits with an associated microvasculature blood supply. It is known 
that low doses of light, specifically visible or near infrared light, may induce an inflammatory response leading to an 
increase in the production of collagen by fibroblasts (collagen producing cells). Fibroblasts are typically triggered by 
mediators released by the vasculature which is generally stimulated by low doses of light.
Osteoblasts (bone producing cells) at a target zone of bone tissue when stimulated by illuminating radiation 
advantageously synthesise new bone tissue ideally improving the structure, strength and general integrity of bone at 
the target zone of bone tissue.
A trans-dermal delivery system, for example including a fibre optic cable or the like, may be used to deliver 
illuminating radiation to a target zone of bone tissue.
Surgical incision is usually necessary to insert the fibre optic cable in the vicinity of the bone tissue. The fibre optic 
cable is generally connected to an external source of illuminating radiation and acts as a means of delivering the 
illuminating radiation to the bone tissue.
Following completion of a period of illuminating radiation, the fibre optic cable is typically removed from the subjects 
body. It therefore follows that for each further period of illuminating radiation that may be required, surgical 
intervention is generally necessary which is time consuming, expensive and may lead to complications prevalent with 
any type of surgery.
An improved method of interacting with a target zone of bone tissue using illuminating radiation has now been 
devised.
According to the present invention there is provided a method of interacting with a target zone of bone tissue using 
illuminating radiation, which method comprises; (i) providing apparatus comprising an illuminating radiation source 
and control means capable of controlling the intensity and/or duration of illuminating radiation emitted by the radiation 
source; (ii) implanting the radiation source in tissue of a subject substantially in the vicinity of (preferably in or 
adjacent to) the target zone of bone tissue, such that the radiation source is implanted substantially below the 
external surface of the subjects skin; and (iii) controlling the intensity and/or duration of illuminating radiation emitted 
by the radiation source; wherein the target zone of bone tissue is interacted with *e according to a controlled regime 
in which at least one period of illuminating radiation is emitted by the implanted radiation source.
The illuminating radiation source may be implanted on the surface of the target zone of bone tissue, or implanted 
within the bone tissue. Alternatively, the illuminating radiation source may be implanted in the vicinity of the target 
zone of bone tissue, for example, for anatomical areas whereby the target zone of bone tissue is surrounded by 
minimal internal biological tissue, the radiation source may be implanted in, adjacent to, or on the surface of the 
surrounding tissue provided the illuminating radiation emitted by the illuminating radiation source can penetrate 
through the surrounding tissue and stimulate osteoblasts in the target zone of bone tissue.
As the radiation source is implanted in the vicinity of the target zone of bone tissue, the bone tissue can 
advantageously receive more than one temporally spaced period of illuminating radiation emitted by the implanted 
radiation source without the need for further surgical intervention.
It is preferred that the controlled regime of interaction with the target zone of bone tissue comprises temporally 
spaced periods of illuminating radiation emitted by the implanted radiation source. The control means 
advantageously allows the radiation source to be activated and deactivated as and when required, according to the 
controlled regime.
The control means preferably enables a predetermined intensity and/or duration of illuminating radiation to be 
selected. The intensity and/or duration of illuminating radiation selected is ideally the optimum intensity and/or 
duration of illuminating radiation for osteoblast stimulation.
It is preferred that the illuminating radiation emitted by the radiation source is substantially in the range 400 nm to 
1000 nm, preferably the illuminating radiation comprises a primary wavelength or narrow wavelength band 
substantially in the range 570 nm to 600 nm or 800 nm to 900 nm.
The illuminating radiation may be pulsed or continuous wave. Pulsed energy may be preferred in order to avoid 
overheating of the tissue in which the illuminating radiation source is implanted and may produce the optimum 
conditions for osteoblast stimulation. Pulse duration is preferably substantially in the range 0 to 0.5 seconds.
The present invention further provides apparatus for interacting with a target zone of bone tissue using illuminating 
radiation, which apparatus comprises an illuminating radiation source and control means capable of controlling the 
intensity and/or duration of illuminating radiation emitted by the radiation source, wherein the radiation source is 
dimensioned and configured to be implanted in tissue of a subject, such that the radiation source is implanted 
substantially below the external surface of the subjects skin.
The illuminating radiation source is preferably arranged to emit temporally spaced periods of illuminating radiation. 
The target zone of bone tissue can thus receive more than one temporally spaced period of illuminating radiation 
using apparatus of the present invention without the need for further surgical intervention.
The illuminating radiation source is preferably arranged to emit illuminating radiation substantially in or about the 
range 400nm to 1000 nm, preferably in the range 570 nm to 600 nm or 800 nm to 900 nm.
The illuminating radiation source preferably emits illuminating radiation at an energy density substantially in the range 
0.5 J/cm2 to 5 J/cm2. The apparatus is preferably configured to inhibit output energies substantially above this range. 
Desirably, the apparatus (preferably the control means) is configured to permit variable selection of energy densities 
within the range.
The illuminating radiation source is preferably arranged to emit pulsed illuminating radiation with a pulse duration 
substantially in the range 0 to 0.5 seconds.
It is preferred feature of the present invention that the illuminating radiation source comprises a Light Emitting 
Diode (LED). Alternatively, other light emitters may be used, such as Laser Diodes. Beneficially, a plurality of light 
emitters are provided, preferably housed in a device housing and operable in concert and/or selectively individually or 
in sub-groups.
It is preferred that the radiation source is substantially inert so that the radiation source can be implanted into tissue 
of a subject for a prolonged period of time without inducing an immune response in the subject.
Apparatus of the present invention may include an implant device comprising the illuminating radiation source and at 
least one further element comprising a power supply system for the illuminating radiation source and/or a control 
system for the illuminating radiation source. The device is dimensioned and configured to be implanted in tissue of a 
subject, such that the device is implanted substantially below the external surface of the subjects skin.
The implant device is preferably substantially surrounded by a housing including at least a transparent portion. The 
housing is advantageously transparent to allow illuminating radiation emitted by the radiation source to pass through 
the housing of the device and penetrate the target zone of bone tissue once the device has been implanted.
The implant device (at least the device housing) is preferably substantially inert so that the device can be implanted 
into tissue of a subject for a prolonged period of time without inducing an immune response in the subject.
The implant device may be substantially elongated and flattened. Alternatively the device may be substantially 
spherical. An elongated and flattened or spherical geometry advantageously allows maximum illumination angles.
Apparatus of the present invention preferably includes a power source. The power source generally powers the 
illuminating radiation source. The power source may also power the control means and other features which may be 
included in apparatus of the present invention.
The power source may be an external power source intended to remain outside a subjects body. Additionally or 
alternatively, an internal power source may be provided, for example, the implant device may include a power source 
such as a battery.
When an external power source is provided, the external power source may be connected to the implanted radiation 
source via one or more electrical connectors. It is therefore preferred in one embodiment that apparatus of the 
present invention includes an electrical connector arranged to connect the radiation source to the power source.
A first electrical connector may be connected at one end to the illuminating radiation source, which radiation source 
is implanted in tissue of a subject. The opposing end of the first electrical connector may be implanted in the subjects 
skin. The end of the first connector implanted in the subjects skin can then be connected to the external power 
source via a second electrical connector.
Upon completion of a period of illuminating radiation emitted by the implanted illuminating radiation source, the 
second electrical connector can be disconnected from the first electrical connector. The first connector typically 
remains implanted in the subjects skin so that if further periods of illuminating radiation are required, the second 
connector can easily be reconnected to the first connector to provide power from the external power source to the 
implanted radiation source.
A remote control and/or power source or supply system may be used, typically comprising a respective power or 
control sub-unit respectively mounted on-board the implant device.
An external power/control unit interacts with the device on-board sub-unit to power/control operation of the device.
An electromagnetic signal remote control system (for example, using Radio-frequency signals) may be employed in 
the present invention. Apparatus of the present invention may therefore include means for receiving electromagnetic 
control signals (such as an antennae capable of receiving
Radio-frequency signals). It is preferred that the signal receiving means is mounted on-board the implant device.
Commands such as activate (operate), deactivate (render inoperable), output power, illuminating radiation 
wavelength, emission duration and the like can be encoded into such signals and transmitted to the signal receiving 
means from a remote control unit so as to control the intensityand/or duration of illuminating radiation emitted by the 
radiation source. The remote control unit may therefore include means for transmitting electromagnetic control 
signals (such as an antennae capable of transmitting radio-frequency signals).
When apparatus of the present invention includes means for receiving control signals from a remote controller unit as 
hereinbefore described, the apparatus may further include conversion means (preferably mounted on-board the 
implant device) capable of converting control signals received by the receiving means into electrical power. The 
electrical1 power generated by the conversion means, may be used to power the radiation source, the control system 
or any other feature included in the apparatus of the present invention.
There is further provided by the present invention a method of setting up apparatus according to the present 
invention for interacting with a target zone of bone tissue using illuminating radiation, which method comprises 
implanting the illuminating radiation source or the implant device in tissue of a subject substantially in the vicinity of 
(preferably in or adjacent to) the target zone of bone tissue, such that the radiation source or the device is implanted 
substantially below the external surface of the subjects skin.
The present invention further provides use of apparatus according to the present invention for interacting with a 
target zone of bone tissue using illuminating radiation.
The illuminating radiation source or the implant device is implanted in tissue of a subject substantially in the vicinity of 
(preferably in or adjacent to) the target zone of bone tissue, such that the radiation source or the device is implanted 
substantially below the external surface of the subjects skin.
The present invention further provides use of a source of illuminating radiation in the manufacture of medicament 
implant apparatus for interacting with a target zone of bone tissue using illuminating radiation.
There is further provided by the present invention bone tissue with an illuminating radiation source implanted therein.
According to a further aspect, the present invention provides apparatus as hereinbefore defined for use in interacting 
with a target zone of bone tissue, the apparatus including an illuminating radiation source implanted in the vicinity of 
the target zone of bone tissue to be substantially below the surface of a subjects skin.
Apparatus for interacting with a target zone of bone tissue using illuminating radiation will now be further described in 
specific embodiments, and by way of example only, with reference to the accompanying drawings in which:
Figure 1 is a schematic plan view of an exemplary apparatus according to the invention;
Figure 2 is a schematic side view of an exemplary apparatus according to the invention;
Figure 3 is a schematic view of an alternative exemplary apparatus according to the invention;
Figure 4 is a schematic view of a further alternative apparatus in accordance with the invention; and
Figure 5 is a schematic view of a further alternative apparatus according to the invention together with a remote
external controller and power source.
Referring to the drawings and initially to Figures 1 and 2, there is shown an implant device 1 with an optically 
transparent housing 2. Device 1 comprises a plurality of individual illuminating radiation emitters 3 (typically 
Light Emitting Diodes (LEDs) or Laser Diodes) positioned within transparent housing 2 (shown most clearly in Figure 
2). The housing 2 of device 1 is transparent to enable illuminating radiation emitted by illuminating radiation emitters 
3 to penetrate surrounding tissue which device 1 may be implanted therein. The illuminating radiation emitters 3 may 
be operated in unison, or individually, or in sub-groups.
Figure 2 shows a control system 4 and a power source 5 encased within the body of devicel. Power source 5 
typically provides power to illuminating radiation emitters 3. Control system 4 typically controls the intensity and/or 
duration of illuminating radiation emitted by illuminating radiation emitters 3. For example, illuminating radiation 
emitters 3 are typically controlled to emit illuminating radiation in a pulsed regime in which the inter-pulse interval is 
sufficient to prevent overheating of the tissue.
Device 1 is preferably inert so that it can be implanted into tissue of a subject for a prolonged period of time without 
inducing an immune response in the subject. Device 1 can be flat and elongated as shown in Figures 1 and 2 or 
spherical as shown in Figure 4. The illuminating radiation emitters 3 shown in Figure 4 are not within the housing 2 of 
device 1 but are instead position on the surface of device 1.
Figure 3 shows an alternative apparatus according to the present invention where an external power source (not 
shown) is provided instead of, or in addition to, an internal power source. An external power source can be 
connected to device 1 via electrical connectors 6 which pass from device 1 to the surface of a subject's skin.
The electrical connectors 6 at the skin surface can be connected to an external power source via further connectors 
(not shown).
The apparatus shown in Figure 5 has a remote external controller 7 with transmitter 8 capable of transmitting 
electromagnetic control signals, such as Radio-frequency signals. The control signals transmitted by transmitter 8 
can be received by receiver 9 positioned on-board device 1.
Both transmitter 8 and receiver 9 may be antennae capable of transmitting and receiving Radio-frequency signals 
respectively. Receiver 9 is connected to a power converter * 10 within the body of device 1.. Power converter 10 can 
convert control signals received by receiver 9 into electrical power to power illuminating radiation emitters 3. 
Additionally or alternatively, control signals sent by controller 7 via transmitter 8, can be used to control the intensity 
and/or duration of illuminating radiation emitted by illuminating radiation emitters 3. Control signals are typically 
received by receiver 9 and transmitted to control system4 to control illuminating radiation emitters 3.
Commands such as activate/deactivate, output power, illuminating radiation wavelength and emission duration can 
be encoded into the control signals transmitted to receiver 9 and acted upon by control system 4.
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CLAIMS: 1. A method of interacting with a targetzonerof bone tissue using illuminating radiation, which method 
comprises ; (i) providing apparatus comprising an illuminating radiation source and control means capable of 
controlling the intensity and/or duration of illuminating radiation emitted by the radiation source; (ii) implanting the 
radiation source in tissue of the subject substantially in the vicinity of the target zone of bone tissue, such that the 
radiation source is implanted substantially below the external surface of the subjects skin; and (iii) controlling the 
intensity and/or duration of illuminating radiation emitted by the radiation source; wherein the target zone of bone 
tissue is interacted with according to a controlled regime in which at least one period of illuminating radiation is 
emitted by the implanted radiation source.
2. A method according to claim 1, wherein the radiation source is implanted substantially in or adjacent to the target 
zone of bone tissue.
3. A method according to claim 1 or 2, wherein the controlled regime of interaction with the target zone of bone tissue 
comprises temporally spaced periods of illuminating radiation emitted by the implanted radiation source.
4. A method according to any preceding claim, wherein the illuminating radiation emitted by the radiation source is of 
a predetermined wavelength, preferably corresponding to the optimum wavelength for osteoblast stimulation.
5. A method according to any preceding claim, wherein the illuminating radiation emitted by the radiation source is 
substantially in the range 400 nm to 1000 nm.
6. A method according to claim 5, wherein the illuminating radiation comprises a primary wavelength or narrow 
wavelength band substantially in the range
570 nm to 600 nm or 800 nm to 900 nm.
7. A method according to any preceding claim, wherein the illumination radiation emitted by the illuminating radiation 
source is pulsed.
8. A method according to claim 7, wherein the pulse duration is substantially in the range 0 seconds to 
0.5 seconds.
9. Apparatus for interacting with a target zone of bone tissue using illuminating radiation, which apparatus comprises 
an illuminating radiation source and control means capable of controlling the intensity and/or duration of illuminating 
radiation emitted by the radiation source, wherein the radiation source is dimensioned and configured to be implanted 
in tissue of a subject, such that the radiation source is implanted substantially below the external surface of the 
subjects skin.
10. Apparatus according to claim 9, wherein the illuminating radiation source is arranged to emit temporally spaced 
periods of illuminating radiation.
11. Apparatus according to claims 9 or10, wherein the illuminating radiation source comprises a Light 
Emitting Diode (LED) and/or Laser Diode.
12. Apparatus according to any of claims 9 to 11, wherein the radiation source is substantially inert.
13. Apparatus according to any of claims 9 to 12, wherein the illuminating radiation source is arranged to emit 
illuminating radiation substantially in or about the range 400 nm to 1000 nm.
14. Apparatus according to claim 13, wherein the illuminating radiation source is arranged to emit illuminating 
radiation substantially in or about the range 570 nm to 600 nm or 800 nm to 900 nm.
15. Apparatus according to any of claims 9 to 14, wherein the illuminating radiation source is arranged to emit 
illuminating radiation at an energy density substantially in the range 0.5J/cm2 to5 J/cm2.
16. Apparatus according to any of claims 9 to 15, wherein the illuminating radiation source is arranged to emit 
illuminating radiation in a pulsed wave with a pulse duration substantially in the range 0 seconds to 0.5 seconds.
17. Apparatus according to any of claims 9 to 16, including a power source.
18. Apparatus according to claim 17, including an electrical connector arranged to connect the radiation source to the 
power source.
19. Apparatus according to any of claims 9 to 18, including a device comprising the illuminating radiation source and 
at least one further element comprising a power supply system for the illuminating radiation source and/or control 
system for the illuminating radiation source, which device is dimensional and configured to be implanted in tissue of a 
subject such that the device is implanted substantially below the external surface of the subjects skin.
20. Apparatus according to claim 19, wherein the device is substantially surrounded by a housing including at least a 
transparent portion.
21. Apparatus according to claim 20, wherein the housing of the device is substantially inert.
22. Apparatus according to any of claims 19 to 21, wherein the device is substantially elongated and flattened. 23. 
Apparatus according to any of claims 19 to 21, wherein the device is substantially spherical.
24. Apparatus according to any of claims 19 to 23, wherein the device includes means for receiving electromagnetic 
signals (such as Radio-frequency signals).
25. Apparatus according to claim 24, wherein the device further includes conversion means arranged to convert 
electromagnetic signals received by the signal receiving means into electrical power.
26. A method of setting up apparatus according to any of claims 9 to 18 for interacting with a target zone of bone 
tissue using illuminating radiation, which method comprises implanting the illuminating radiation source in tissue of a 
subject substantially in the vicinity of (preferably in or adjacent to) the target zone of bone tissue, such that the 
radiation source is implanted substantially below the external surface of the subjects skin.
27. A method of setting up apparatus according to any of claims 19 to 25, for interacting with a target zone of bone 
tissue using illuminating radiation, which method comprises implanting the device in tissue of a subject substantially 
in the vicinity of (preferably in or adjacent to) the target zone of bone tissue, such that the device is implanted 
substantially below the external surface of the subjects skin.
28. Use of apparatus according to any of claims 9 to 18, for interacting with a target zone of bone tissue using 
illuminating radiation.
29. Use according to claim 28, wherein the illuminating radiation source is implanted in the tissue of a subject 
substantially in the vicinity of (preferably in or adjacent to) the target zone of bone tissue, such that the radiation 
source is implanted substantially below the external surface of the subjects skin.
30. Use of apparatus according to any of claims 19 to 25, for interacting with a target zone of bone tissue using 
illuminating radiation.
31. Use according to claim 30, wherein the device is implanted in tissue of a subject substantially in the vicinity of 
(preferably in or adjacent to) the target zone of bone tissue, such that the device is implanted substantially below the 
external surface of the subjects skin.
32. Use of a source of illuminating radiation in the manufacture of medicament implant apparatus for interacting with 
a target zone of bone tissue using illuminating radiation.
33. Bone tissue with an illuminating radiation source implanted therein. 34. Apparatus for use in interacting with a 
target zone of bone tissue, which apparatus includes an illuminating radiation source implanted in the vicinity of the 
target zone of bone tissue, to be substantially below the surface of a subjects skin.
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